<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events - Zhan, S - 2018 | Cochrane Library</title> <meta content="Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events - Zhan, S - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012502.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events - Zhan, S - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012502.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012502.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events" name="citation_title"/> <meta content="Shipeng Zhan" name="citation_author"/> <meta content="First Affiliated Hospital of Third Military Medical University (Army Medical University)" name="citation_author_institution"/> <meta content="Min Tang" name="citation_author"/> <meta content="First Affiliated Hospital of Third Military Medical University (Army Medical University)" name="citation_author_institution"/> <meta content="Fang Liu" name="citation_author"/> <meta content="First Affiliated Hospital of Third Military Medical University (Army Medical University)" name="citation_author_institution"/> <meta content="Peiyuan Xia" name="citation_author"/> <meta content="First Affiliated Hospital of Third Military Medical University (Army Medical University)" name="citation_author_institution"/> <meta content="peiyuan_xia@163.com" name="citation_author_email"/> <meta content="Maoqin Shu" name="citation_author"/> <meta content="First Affiliated Hospital of Third Military Medical University (Army Medical University)" name="citation_author_institution"/> <meta content="Xiaojiao Wu" name="citation_author"/> <meta content="Third Military Medical University (Army Medical University)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012502.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/11/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012502.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012502.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012502.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticholesteremic Agents [adverse effects, *therapeutic use]; Cardiovascular Diseases [mortality, *prevention &amp; control]; Cause of Death; Cholesterol [blood]; Cholesterol, LDL [blood]; Drug Therapy, Combination; Ezetimibe [adverse effects, *therapeutic use]; Fenofibrate [therapeutic use]; Hydroxymethylglutaryl‐CoA Reductase Inhibitors [therapeutic use]; Myocardial Infarction [mortality, prevention &amp; control]; Randomized Controlled Trials as Topic; Simvastatin [adverse effects, therapeutic use]; Stroke [mortality, prevention &amp; control]; Triglycerides [blood]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012502.pub2&amp;doi=10.1002/14651858.CD012502.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012502\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012502\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","hr","fr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012502.pub2",title:"Ezetimibe for the prevention of cardiovascular disease and all\\u2010cause mortality events",firstPublishedDate:"Nov 19, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012502.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012502.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012502.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012502.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012502.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012502.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012502.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012502.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012502.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012502.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17404 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012502.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-sec-0119"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-sec-0113"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/appendices#CD012502-sec-0124"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/table_n/CD012502StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/table_n/CD012502StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information#CD012502-cr-0002">Shipeng Zhan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information#CD012502-cr-0003">Min Tang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information#CD012502-cr-0004">Fang Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information#CD012502-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Peiyuan Xia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information#CD012502-cr-0006">Maoqin Shu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information#CD012502-cr-0007">Xiaojiao Wu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information/en#CD012502-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 November 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012502.pub2">https://doi.org/10.1002/14651858.CD012502.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012502-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012502-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012502-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012502-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012502-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012502-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012502-abs-0001" lang="en"> <section id="CD012502-sec-0001"> <h3 class="title" id="CD012502-sec-0001">Background</h3> <p>Cardiovascular disease (CVD) remains an important cause of mortality and morbidity, and high levels of blood cholesterol are thought to be the major modifiable risk factors for CVD. The use of statins is the preferred treatment strategy for the prevention of CVD, but some people at high‐risk for CVD are intolerant to statin therapy or unable to achieve their treatment goals with the maximal recommended doses of statin. Ezetimibe is a selective cholesterol absorption inhibitor, whether it has a positive effect on CVD events remains uncertain. Results from clinical studies are inconsistent and a thorough evaluation of its efficacy and safety for the prevention of CVD and mortality is necessary. </p> </section> <section id="CD012502-sec-0002"> <h3 class="title" id="CD012502-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of ezetimibe for the prevention of CVD and all‐cause mortality. </p> </section> <section id="CD012502-sec-0003"> <h3 class="title" id="CD012502-sec-0003">Search methods</h3> <p>We searched the CENTRAL, MEDLINE, Embase and Web of Science on 27 June 2018, and two clinical trial registry platforms on 11 July 2018. We checked reference lists from primary studies and review articles for additional studies. No language restrictions were applied. </p> </section> <section id="CD012502-sec-0004"> <h3 class="title" id="CD012502-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared ezetimibe versus placebo or ezetimibe plus other lipid‐modifying drugs versus other lipid‐modifying drugs alone in adults, with or without CVD, and which had a follow‐up of at least 12 months. </p> </section> <section id="CD012502-sec-0005"> <h3 class="title" id="CD012502-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies for inclusion, extracted data, assessed risk of bias and contacted trialists to obtain missing data. We performed statistical analyses according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and used the GRADE to assess the quality of evidence. </p> </section> <section id="CD012502-sec-0006"> <h3 class="title" id="CD012502-sec-0006">Main results</h3> <p>We included 26 RCTs randomising 23,499 participants. All included studies assessed effects of ezetimibe plus other lipid‐modifying drugs compared with other lipid‐modifying drugs alone or plus placebo. Our findings were driven by the largest study (IMPROVE‐IT), which had weights ranging from 41.5% to 98.4% in the different meta‐analyses. </p> <p>Ezetimibe with statins probably reduces the risk of major adverse cardiovascular events compared with statins alone (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.90 to 0.98; a decrease from 284/1000 to 267/1000, 95% CI 256 to 278; 21,727 participants; 10 studies; moderate‐quality evidence). Trials reporting all‐cause mortality used ezetimibe with statin or fenofibrate and found they have little or no effect on this outcome (RR 0.98, 95% CI 0.91 to 1.05; 21,222 participants; 8 studies; high‐quality evidence). Adding ezetimibe to statins probably reduces the risk of non‐fatal myocardial infarction (MI) (RR 0.88, 95% CI 0.81 to 0.95; a decrease from 105/1000 to 92/1000, 95% CI 85 to 100; 21,145 participants; 6 studies; moderate‐quality evidence) and non‐fatal stroke (RR 0.83, 95% CI 0.71 to 0.97; a decrease 32/1000 to 27/1000, 95% CI 23 to 31; 21,205 participants; 6 studies; moderate‐quality evidence). Trials reporting cardiovascular mortality added ezetimibe to statin or fenofibrate, probably having little or no effect on this outcome (RR 1.00, 95% CI 0.89 to 1.12; 19457 participants; 6 studies; moderate‐quality evidence). The need for coronary revascularisation might be reduced by adding ezetimibe to statin (RR 0.94, 95% CI 0.89 to 0.99; a decrease from 196/1000 to 184/1000, 95% 175 to 194; 21,323 participants; 7 studies); however, no difference in coronary revascularisation rate was observed when a sensitivity analysis was limited to studies with a low risk of bias. </p> <p>In terms of safety, adding ezetimibe to statins may make little or no difference in the risk of hepatopathy (RR 1.14, 95% CI 0.96 to 1.35; 20,687 participants; 4 studies; low‐quality evidence). It is uncertain whether ezetimibe increase or decrease the risk of myopathy (RR 1.31, 95% CI 0.72 to 2.38; 20,581 participants; 3 studies; very low‐quality evidence) and rhabdomyolysis, given the wide CIs and low event rate. Little or no difference in the risk of cancer, gallbladder‐related disease and discontinuation due to adverse events were observed between treatment groups. For serum lipids, adding ezetimibe to statin or fenofibrate might further reduce the low‐density lipoprotein cholesterol (LDL‐C), total cholesterol and triglyceride levels and likely increase the high‐density lipoprotein cholesterol levels; however, substantial heterogeneity was detected in most analyses. </p> <p>None of the included studies reported on health‐related quality of life.</p> </section> <section id="CD012502-sec-0007"> <h3 class="title" id="CD012502-sec-0007">Authors' conclusions</h3> <p>Moderate‐ to high‐quality evidence suggests that ezetimibe has modest beneficial effects on the risk of CVD endpoints, primarily driven by a reduction in non‐fatal MI and non‐fatal stroke, but it has little or no effect on clinical fatal endpoints. The cardiovascular benefit of ezetimibe might involve the reduction of LDL‐C, total cholesterol and triglycerides. There is insufficient evidence to determine whether ezetimibe increases the risk of adverse events due to the low and very low quality of the evidence. The evidence for beneficial effects was mainly obtained from individuals with established atherosclerotic cardiovascular disease (ASCVD, predominantly with acute coronary syndrome) administered ezetimibe plus statins. However, there is limited evidence regarding the role of ezetimibe in primary prevention and the effects of ezetimibe monotherapy in the prevention of CVD, and these topics thus requires further investigation. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012502-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012502-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012502-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012502-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012502-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012502-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012502-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012502-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012502-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012502-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012502-abs-0005" lang="en"> <h3>Ezetimibe for the prevention of heart disease and death</h3> <p><b>Review question</b> </p> <p>Is taking ezetimibe safe and does it prevent heart disease and death?</p> <p><b>Background</b> </p> <p>Heart disease remains the leading cause of death worldwide, and controlling lipid levels is one of the most effective strategies for preventing heart disease. The use of statins is the preferred treatment strategy for the prevention of heart disease, but some people at high risk of heart disease are intolerant to statins or with a poor response to statin therapy. Ezetimibe is a non‐statin drug that can reduce the blood lipids levels by inhibiting cholesterol absorption, but whether it has beneficial effects on heart disease and death remains uncertain. </p> <p><b>Study characteristics</b> </p> <p>This evidence is current up to July 2018. We included 26 studies involving 23,499 participants. These studies assessed the effects of ezetimibe plus other lipid‐lowering drugs versus lipid‐lowering drugs alone for heart disease. The participants were adults, and most of them had been diagnosed with coronary heart disease. </p> <p><b>Key results</b> </p> <p>Ezetimibe with statins probably reduces the risk for combined outcome of death due to heart disease, heart attack or stroke, but the benefit is moderate. However, adding ezetimibe to statin or fenofibrate have little or no effect on death from any cause. Treatment with ezetimibe and statin probably reduces the risk for non‐fatal heart attacks and non‐fatal stroke. Adding ezetimibe to statin or fenofibrate probably have little or no effect on heart‐related death. Ezetimibe with statins might reduce the need for coronary revascularisation (the restoration of an adequate blood supply to the heart) by means of surgery. </p> <p>In terms of safety, we do not have enough evidence to know whether ezetimibe increases or decreases side‐effects (e.g. liver injury, muscle pain, cancer, gallbladder‐related disease and discontinuation). The analysis of blood lipids revealed that the addition of ezetimibe statin or fenofibrate therapy might further reduce the levels of blood lipids, including low‐density lipoprotein cholesterol ('bad' cholesterol), total cholesterol and triglycerides, and likely increased the level of high‐density lipoprotein cholesterol ('good' cholesterol). None of the included studies reported on health‐related quality of life. There is a lack of evidence supporting the use of ezetimibe monotherapy for the prevention of heart disease, and this topic requires further investigation. </p> <p><b>Quality of evidence</b> </p> <p>The quality of evidence ranged from high to very low across the outcomes.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012502-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012502-sec-0119">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012502-sec-0175">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012502-sec-0119"></div> <h3 class="title" id="CD012502-sec-0120">Implications for practice</h3> <section id="CD012502-sec-0120"> <p>Moderate‐ to high‐quality evidence suggests that ezetimibe has modest beneficial effects on the risk of cardiovascular disease (CVD) endpoints, primarily driven by a reduction in non‐fatal myocardial infarction (MI) and non‐fatal stroke, but it has little or no effect on clinical fatal endpoints (all‐cause mortality and cardiovascular mortality). The cardiovascular benefit of ezetimibe might involve reductions in low‐density lipoprotein cholesterol (LDL‐C), total cholesterol (TC) and triglyceride (TG). There is insufficient evidence to determine whether ezetimibe increases the risk of adverse events (AEs), including incidence of hepatopathy, myopathy, rhabdomyolysis, cancer, gallbladder‐related disease and discontinuation due to AEs, due to the low and very low quality of the evidence. The evidence for beneficial effects was mainly derived from individuals with established atherosclerotic cardiovascular disease (ASCVD) (predominantly with acute coronary syndrome (ACS)) who were administered ezetimibe plus statins, but there is limited evidence for the role of ezetimibe in primary prevention. Therefore, the addition of ezetimibe to statin therapy might be an alternative treatment for patients at high risk of ASCVD who are unable to tolerate the recommended statin intensities or fail to achieve their treatment goals. </p> </section> <h3 class="title" id="CD012502-sec-0121">Implications for research</h3> <section id="CD012502-sec-0121"> <p>First, the effects of ezetimibe monotherapy for the prevention of CVD are currently unknown and need to be further investigated. </p> <p>Second, subgroup analysis performed in IMPROVE‐IT study suggests a more favourable treatment effect on diabetic and elderly (aged at least 75 years) individuals. However, the evidence originated from a single study, and thus, more studies are required to further confirm this finding. </p> <p>Third, the IMPROVE‐IT study generally used a moderate‐intensity statin (40 mg/day simvastatin), but high‐intensity statin therapy is currently recommended for the treatment of patients with ACS. There remains a lack of evidence to assess the effects of ezetimibe in combination with moderate‐ or high‐intensity statin versus high‐intensity statin alone on cardiovascular endpoints. </p> <p>Fourth, similar findings can be observed in the meta‐analysis recently published by Cochrane regarding the clinical efficacy of PCSK9 antibodies (<a href="./references#CD012502-bbs2-0134" title="SchmidtAF , PearceLS , WilkinsJT , OveringtonJP , HingoraniAD , CasasJP . PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD011748.pub2] ">Schmidt 2017</a>), which revealed that the effect on major adverse cardiovascular events (MACE) was less efficient than expected and likewise the fatal endpoint was not affected. However, the Cholesterol Treatment Trialists (CTT) meta‐analysis (<a href="./references#CD012502-bbs2-0103" title="Cholesterol Treatment Trialists Collaboration, MihaylovaB , EmbersonJ , BlackwellL , KeechA , SimesJ , BarnesEH , et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta‐analysis of individual data from 27 randomised trials. Lancet2012;380(9841):581‐90. ">CTT 2012</a>) of statin trials showed a significant reduction in risk for MACE and all‐cause death with every mmol/L of LDL‐C level reduction (RR = 0.79, P &lt; 0.0001 and RR = 0.91 P &lt; 0.0001, respectively). These observations should encourage medical research toward a more in‐depth study of the relationship between the decrease in LDL‐C and the clinical endpoint (also in view of the cost of new classes of lipid‐lowering drugs). </p> <p>Finally, results from our study, alongside with the results of the PCSK9 antibodies review, suggest that a) other ways of lowering LDL‐C, or b) targeting novel targets in the lipid metabolism, c) inflammatory pathways, or d) other processes leading to atherosclerotic plaque formation should be pursued in the future for a more pronounced reduction in fatal cardiovascular endpoints in this group of patients. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012502-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012502-sec-0029"></div> <div class="table" id="CD012502-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ezetimibe plus other lipid‐modifying drugs compared to other lipid‐modifying drugs alone or plus placebo for the prevention of cardiovascular disease and all‐cause mortality events</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cardiovascular disease or at high risk of cardiovascular disease<br/> <b>Setting:</b> inpatients or outpatient<br/> <b>Intervention:</b> ezetimibe plus other lipid‐modifying drugs (statin or fenofibrate)<br/> <b>Comparison:</b> other lipid‐modifying drugs (statin or fenofibrate) alone or plus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other lipid‐modifying drugs alone or plus placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Ezetimibe plus other lipid‐modifying drugs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major adverse cardiovascular events (MACE)<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.90 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,727<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 88.8% of the weight.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1,000<br/> (256 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.91 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,222<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The IMPROVE‐IT study carried 94.6% of the weight.</p> <p>Two additional studies reported that no deaths occurred, and one study reported the total deaths but did not provide data by treatment arm. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1,000<br/> (112 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction (non‐fatal)<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.81 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,145<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 97.8% of the weight, and also provided data on any MI (HR 0.87, 95% CI 0.80 to 0.95) and fatal MI (HR 0.84, 95% CI 0.55 to 0.1.27). </p> <p>Two additional studies reported that no MI events occurred.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/> (85 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke (non‐fatal)<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/> (0.71 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,205<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 89.4% of the weight, and also provided data on any stroke (HR 0.86, 95% CI 0.73 to 1.00), ischaemic stroke (HR 0.79, 95% CI 0.67 to 0.94), haemorrhagic stroke (HR 1.38, 95% CI 0.93 to 2.04) and fatal stroke (HR 1.22, 95% CI 0.81 to 1.82). </p> <p>One additional study reported that no stroke events occurred.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1,000<br/> (23 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/> (0.89 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19,457<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The IMPROVE‐IT study carried 98.4% of the weight.</p> <p>Four additional studies reported that no cardiovascular death occurred and one study reported total cardiac deaths but did not provide data by treatment arm. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1,000<br/> (50 to 63) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ hepatopathy<br/> follow‐up: range 1 to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/> (0.96 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20,687<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 89.6% of the weight.</p> <p>Ten additional studies reported no occurrence in the levels of ALT and/or AST being more than or equal 3 x ULN. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/> (22 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ myopathy<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.31<br/> (0.72 to 2.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20,581<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 52.5% of the weight.</p> <p>Thirteen additional studies reported that none of the participants in either group developed a CK level more than or equal 10 x ULN. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/> (1 to 4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to risk of bias. </p> <p><sup>2</sup> Downgraded by one level due to imprecision (the 95% CI exclude serious harm, but included the null). </p> <p><sup>3</sup> Downgraded by one level due to imprecision (the 95% CI of the overall effect included both no effect and important harm). </p> <p><sup>4</sup> Downgraded by two levels due to imprecision (few events and wide CI). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012502-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012502-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012502-sec-0137">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012502-sec-0030"></div> <section id="CD012502-sec-0031"> <h3 class="title" id="CD012502-sec-0031">Description of the condition</h3> <p>Cardiovascular disease (CVD) is a group of disorders of the heart and blood vessels, including coronary heart disease (heart attacks), cerebrovascular disease (stroke), hypertensive heart disease, heart failure, peripheral artery disease, rheumatic heart disease, congenital heart disease and other conditions (<a href="./references#CD012502-bbs2-0143" title="World Health Organization. Cardiovascular diseases. www.who.int/topics/cardiovascular_diseases/en/ (accessed 15 March 2016). ">WHO 2016</a>). CVD remains the leading cause of death worldwide, is an increasing cause of morbidity and a major cause of disability and ill‐health (<a href="./references#CD012502-bbs2-0121" title="MozaffarianD , BenjaminEJ , GoAS , ArnettDK , BlahaMJ , CushmanM , et al. Heart disease and stroke statistics ‐ 2016 update: a report from the American Heart Association. Circulation2016;133(4):e38‐e360. ">Mozaffarian 2016</a>; <a href="./references#CD012502-bbs2-0122" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2950‐9. ">Nichols 2014</a>; <a href="./references#CD012502-bbs2-0131" title="RothGA , ForouzanfarMH , MoranAE , BarberR , NguyenG , FeiginVL , et al. Demographic and epidemiologic drivers of global cardiovascular mortality. New England Journal of Medicine2015;372(14):1333‐41. ">Roth 2015a</a>; <a href="./references#CD012502-bbs2-0142" title="World Health Organization. Cardiovascular diseases (CVDs) [Fact sheet number 317, Updated January 2015]. www.who.int/mediacentre/factsheets/fs317/en/ (accessed 15 March 2016). ">WHO 2015</a>). An estimated 17.5 million people died from CVDs in 2012, accounting for 31% of deaths globally from all causes (<a href="./references#CD012502-bbs2-0142" title="World Health Organization. Cardiovascular diseases (CVDs) [Fact sheet number 317, Updated January 2015]. www.who.int/mediacentre/factsheets/fs317/en/ (accessed 15 March 2016). ">WHO 2015</a>). Of these deaths, an estimated 7.4 million and 6.7 million were due to coronary heart disease and stroke, respectively. The burden of the disease is particularly high in low‐ and middle‐income countries, where over 75% of CVD deaths occur (<a href="./references#CD012502-bbs2-0108" title="Global Burden of Disease (GBD) 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all‐cause mortality, and cause‐specific mortality for 249 causes of death, 1980‐2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet2016;388(10053):1459‐544. ">GBD 2016</a>; <a href="./references#CD012502-bbs2-0132" title="RothGA , HuffmanMD , MoranAE , FeiginV , MensahGA , NaghaviM , et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation2015;132(17):1667‐78. ">Roth 2015b</a>). The health burden of CVD is also accompanied by a significant harmful economic impact at both national and household levels. The global cost of CVD in 2010 was estimated at USD 863 billion (an average per capita cost of USD 125), and that figure is projected to rise to at least USD 1044 billion in 2030, an increase of 22% (<a href="./references#CD012502-bbs2-0100" title="BloomDE , CafieroET , Jané‐LlopisE , Abrahams‐GesselS , BloomLR , FathimaS , et al. The Global Economic Burden of Non‐communicable Diseases. Geneva: World Economic Forum2011. ">Bloom 2011</a>). CVD produces immense health and economic burdens globally, therefore preventing deaths and diseases due to CVD is a priority for global public health. </p> <p>CVD is multi‐factorial in its causation. One of the major modifiable risk factors for CVD is thought to be high levels of blood cholesterol (hypercholesterolaemia), therefore lowering cholesterol, in particular low‐density lipoprotein cholesterol (LDL‐C), is considered an important target of therapy in the primary and secondary prevention of CVD (<a href="./references#CD012502-bbs2-0109" title="GrundySM , CleemanJI , MerzCN , BrewerHBJr , ClarkLT , HunninghakeDB , et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation2004;110(2):227‐39. ">Grundy 2004</a>; <a href="./references#CD012502-bbs2-0126" title="Prospective Studies Collaboration, LewingtonS , WhitlockG , ClarkeR , SherlikerP , EmbersonJ , et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta‐analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet2007;370(9602):1829‐39. ">PSC 2007</a>; <a href="./references#CD012502-bbs2-0137" title="StoneNJ , RobinsonJG , LichtensteinAH , Bairey MerzCN , BlumCB , EckelRH , et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):S1‐45. ">Stone 2014</a>). </p> </section> <section id="CD012502-sec-0032"> <h3 class="title" id="CD012502-sec-0032">Description of the intervention</h3> <p>Ezetimibe is a non‐statin lipid‐modifying drug, which is the first and only selective inhibitor of intestinal cholesterol absorption. It is an effective LDL‐C lowering agent, which is safe and well‐tolerated. A standard dose of 10 mg a day of ezetimibe lowers LDL‐C by 13% to 20%, non‐high density lipoprotein cholesterol (non‐HDL‐C) by 14% to 19%, and triglyceride (TG) by 5% to 11%, and increases HDL‐C by 3% to 5% (<a href="./references#CD012502-bbs2-0114" title="JacobsonTA , ItoMK , MakiKC , OrringerCE , BaysHE , JonesPH , et al. National lipid association recommendations for patient‐centered management of dyslipidemia: part 1‐ full report. Journal of Clinical Lipidology2015;9(2):129‐69. ">Jacobson 2015</a>). Ezetimibe in combination with other lipid‐modifying agents can lead to superior lipid outcomes and does not increase the rate of adverse reactions (<a href="./references#CD012502-bbs2-0110" title="GudzuneKA , MonroeAK , SharmaR , RanasinghePD , ChelladuraiY , RobinsonKA . Effectiveness of combination therapy with statin and another lipid‐modifying agent compared with intensified statin monotherapy: a systematic review. Annals of Internal Medicine2014;160(7):468‐76. ">Gudzune 2014</a>; <a href="./references#CD012502-bbs2-0125" title="PhanBA , DayspringTD , TothPP . Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management2012;8:415‐27. ">Phan 2012</a>). Furthermore, it does not affect the activity of CYP450, a major drug metabolising enzyme, so avoiding any potential pharmacokinetic interactions with most medications (<a href="./references#CD012502-bbs2-0117" title="KosoglouT , StatkevichP , Johnson‐LevonasAO , PaoliniJF , BergmanAJ , AltonKB . Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clinical Pharmacokinetics2005;44(5):467‐94. ">Kosoglou 2005</a>). Ezetimibe is indicated for the treatment of primary hyperlipidaemia, either alone or in combination with statins; mixed hyperlipidaemia in combination with fenofibrate, simvastatin or atorvastatin; homozygous familial hypercholesterolaemia in combination with atorvastatin or simvastatin; and homozygous sitosterolaemia. </p> </section> <section id="CD012502-sec-0033"> <h3 class="title" id="CD012502-sec-0033">How the intervention might work</h3> <p>Ezetimibe is a selective cholesterol absorption inhibitor that blocks the intestinal absorption of dietary and biliary cholesterol, as well as related plant sterols, without affecting the uptake of fat‐soluble vitamins, triglycerides or bile acids (<a href="./references#CD012502-bbs2-0139" title="SudhopT , ReberM , TribbleD , SapreA , TaggartW , GibbonsP , et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. Journal of Lipid Research2009;50(10):2117‐23. ">Sudhop 2009</a>). It localises to the brush border of the small intestine and reduces the enterocyte uptake and absorption of cholesterol and plant sterols by binding to the Niemann‐Pick C1 Like 1 (NPC1L1) protein (<a href="./references#CD012502-bbs2-0097" title="AltmannSW , DavisHRJr , ZhuLJ , YaoX , HoosLM , TetzloffG , et al. Niemann‐Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science2004;303(5661):1201‐4. ">Altmann 2004</a>; <a href="./references#CD012502-bbs2-0115" title="JiaL , BettersJL , YuL . Niemann‐pick C1‐like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annual Review of Physiology2011;73:239‐59. ">Jia 2011</a>). It can therefore decrease the delivery of intestinal cholesterol to the liver, leading to a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood (<a href="./references#CD012502-bbs2-0097" title="AltmannSW , DavisHRJr , ZhuLJ , YaoX , HoosLM , TetzloffG , et al. Niemann‐Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science2004;303(5661):1201‐4. ">Altmann 2004</a>; <a href="./references#CD012502-bbs2-0117" title="KosoglouT , StatkevichP , Johnson‐LevonasAO , PaoliniJF , BergmanAJ , AltonKB . Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clinical Pharmacokinetics2005;44(5):467‐94. ">Kosoglou 2005</a>; <a href="./references#CD012502-bbs2-0138" title="SudhopT , LutjohannD , KodalA , IgelM , TribbleDL , ShahS , et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation2002;106(15):1943‐8. ">Sudhop 2002</a>). A study confirmed that ezetimibe could reduce intestinal cholesterol absorption by 54% (<a href="./references#CD012502-bbs2-0138" title="SudhopT , LutjohannD , KodalA , IgelM , TribbleDL , ShahS , et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation2002;106(15):1943‐8. ">Sudhop 2002</a>). As the effect of ezetimibe is mainly in the enterohepatic circulation, thereby limiting systemic exposure, it is less likely to cause adverse drug interactions (<a href="./references#CD012502-bbs2-0141" title="VanHeekM , FarleyC , ComptonDS , HoosL , AltonKB , SybertzEJ , et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. British Journal of Pharmacology2000;129(8):1748‐54. ">Van Heek 2000</a>). In addition, ezetimibe was shown to have some pleiotropic effects, including the improvement of inflammation, insulin resistance, fatty liver and so on, although the potential mechanisms for these benefits have not been fully elucidated and have not been related to improved clinical outcomes (<a href="./references#CD012502-bbs2-0120" title="LioudakiE , GanotakisES , MikhailidisDP . Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Current Vascular Pharmacology2011;9(1):62‐86. ">Lioudaki 2011</a>). </p> </section> <section id="CD012502-sec-0034"> <h3 class="title" id="CD012502-sec-0034">Why it is important to do this review</h3> <p>Control of lipid levels is one of the most effective strategies for CVD prevention. Statin therapy is currently the cornerstone of treatment for lowering LDL‐C in the vast majority of individuals with increased risk for CVD (<a href="./references#CD012502-bbs2-0124" title="PerkJ , DeBackerG , GohlkeH , GrahamI , ReinerZ , VerschurenM , et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). European Heart Journal2012;33(13):1635‐701. ">Perk 2012</a>; <a href="./references#CD012502-bbs2-0137" title="StoneNJ , RobinsonJG , LichtensteinAH , Bairey MerzCN , BlumCB , EckelRH , et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):S1‐45. ">Stone 2014</a>). More intensive LDL‐C lowering (compared with less intensive LDL‐C lowering) based on statin monotherapy steadily reduced clinical outcomes in people with cardiovascular risk (<a href="./references#CD012502-bbs2-0102" title="Cholesterol Treatment Trialists Collaboration, BaigentC , BlackwellL , EmbersonJ , HollandLE , ReithC , BhalaN , et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta‐analysis of data from 170,000 participants in 26 randomised trials. Lancet2010;376(9753):1670‐81. ">CTT 2010</a>; <a href="./references#CD012502-bbs2-0103" title="Cholesterol Treatment Trialists Collaboration, MihaylovaB , EmbersonJ , BlackwellL , KeechA , SimesJ , BarnesEH , et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta‐analysis of individual data from 27 randomised trials. Lancet2012;380(9841):581‐90. ">CTT 2012</a>). However, some people have contraindications or intolerance to statin therapy, particularly people at high cardiovascular risk (<a href="./references#CD012502-bbs2-0128" title="ReinerZ . Resistance and intolerance to statins. Nutrition, Metabolism and Cardiovascular Diseases2014;24(10):1057‐66. ">Reiner 2014</a>). Adverse effects are more common with higher‐intensity statin regimens. Therefore, the combination of non‐statin lipid‐modifying drugs with the lowest statin dose tolerated or, as an alternative, a combination of non‐statin lipid‐modifying drugs, represent possible approaches for people intolerant to statins. Due to the lack of convincing clinical evidence, however, the optimal treatment strategy for people who cannot tolerate statin therapy or those who need additional lipid‐modifying therapy is unclear. </p> <p>The American College of Cardiology/American Heart Association (ACC/AHA) guidelines state that there is no evidence supporting the routine use of non‐statin drugs with statin therapy for incremental atherosclerotic cardiovascular disease (ASCVD) risk reduction (<a href="./references#CD012502-bbs2-0137" title="StoneNJ , RobinsonJG , LichtensteinAH , Bairey MerzCN , BlumCB , EckelRH , et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):S1‐45. ">Stone 2014</a>). The guideline recommends that clinicians consider the addition of a non‐statin cholesterol‐lowering drug for people at high‐risk of ASCVD with insufficient response to statin therapy, or for people who are intolerant to the recommended statin intensity. Similarly, the National Lipid Association (NLA) recommendations for people who cannot tolerate a statin say that a non‐statin drug alone or in combination with another cholesterol‐lowering agent may be considered (<a href="./references#CD012502-bbs2-0114" title="JacobsonTA , ItoMK , MakiKC , OrringerCE , BaysHE , JonesPH , et al. National lipid association recommendations for patient‐centered management of dyslipidemia: part 1‐ full report. Journal of Clinical Lipidology2015;9(2):129‐69. ">Jacobson 2015</a>). According to the guidelines above and other current guidelines on the management of dyslipidaemia or the prevention of CVD (<a href="./references#CD012502-bbs2-0105" title="Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia‐‐full report. Journal of Clinical Lipidology2014;8(1):29‐60. ">EDP 2014</a>; <a href="./references#CD012502-bbs2-0127" title="RabarS , HarkerM , O'FlynnN , WierzbickiAS , Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ2014;349:g4356. ">Rabar 2014</a>), non‐statin treatments are not routinely used as monotherapy to decrease LDL‐C concentrations, unless people with CVD are intolerant to statins and they are recommended as combination therapy with statins in high‐risk patients when their treatment goals are not reached with the maximal tolerated dose of a statin. Ezetimibe, which is a non‐statin drug and acts via a novel mechanism, can be combined with a statin to provide complementary cholesterol reduction. The combination therapy enables a more efficient reduction of LDL‐C levels beyond that which can be achieved by statin monotherapy. In addition, clinical trials have reported that ezetimibe demonstrates a favourable safety profile without severe adverse events. However, whether ezetimibe can reduce the rate of cardiovascular events is uncertain. Also, it is unclear whether its combination with other lipid‐modifying agents can reduce the rate of cardiovascular events further compared with other lipid‐modifying agents monotherapy. A number of clinical studies evaluating the use of ezetimibe therapy have resulted in inconsistent data regarding its safety and efficacy (<a href="./references#CD012502-bbs2-0098" title="BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. ">Baigent 2011</a>; <a href="./references#CD012502-bbs2-0101" title="CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. ">Cannon 2015</a>; <a href="./references#CD012502-bbs2-0116" title="KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. ">Kastelein 2008</a>; <a href="./references#CD012502-bbs2-0130" title="RosseboAB , PedersenTR , BomanK , BrudiP , ChambersJB , EgstrupK , et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. New England Journal of Medicine2008;359(13):1343‐56. ">Rossebo 2008</a>), so it is necessary to evaluate published evidence on efficacy and safety of ezetimibe for the prevention of CVD events and mortality. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012502-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012502-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012502-sec-0142">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012502-sec-0035"></div> <p>To assess the efficacy and safety of ezetimibe versus placebo or ezetimibe plus other lipid‐modifying drugs versus other lipid‐modifying drugs alone for the prevention of cardiovascular disease (CVD) events and all‐cause mortality events. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012502-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012502-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012502-sec-0143">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012502-sec-0036"></div> <section id="CD012502-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012502-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with a follow‐up of at least 12 months. We included studies reported as full text, those published as abstract only, and unpublished data. Cluster‐RCTs, cross‐over trials and non‐randomised studies were ineligible for this review, and we excluded them during title and abstract screening. </p> <p>We restricted the follow‐up time of at least 12 months because only long‐term clinical trials may provide sufficient and reliable intervention effects on mortality and cardiovascular morbidity. Guidance on clinical investigation of medicinal products in the treatment of lipid disorders that published by EMA (European Medicines Agency) recommend that a sufficient cohort of patients should be continuously exposed to the drug for at least one year to obtain long‐term effects and safety data (<a href="./references#CD012502-bbs2-0106" title="European Medicines Agency (EMA). Committee for Medicinal Products For Human Use. Note for guidance on clinical investigation of medicinal products in the treatment of lipid disorders. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003235.pdf (accessed 1 December 2016). ">EMA 2004</a>). </p> </section> <section id="CD012502-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adults aged at least 18 years, with or without established CVD.</p> <p>Where studies only included a subset of participants eligible for our review, we contacted the study authors for details on only those participants which met our inclusion criteria. If this was not possible, we planned only to include the trial if it presented the outcomes for eligible participants in a separate subgroup. </p> </section> <section id="CD012502-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Ezetimibe can be administered as monotherapy or as combination therapy with other lipid‐modifying drug(s) with no restriction on dosage and frequency. We included the following comparisons. </p> <p> <ol id="CD012502-list-0001"> <li> <p>Ezetimibe versus placebo</p> </li> <li> <p>Ezetimibe plus other lipid‐modifying drug(s) versus other lipid‐modifying drug(s) alone or plus placebo </p> </li> </ol> </p> </section> <section id="CD012502-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD012502-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012502-list-0002"> <li> <p>Major adverse cardiovascular events (MACE), defined as a composite outcome of cardiovascular death, non‐fatal myocardial infarction (MI), non‐fatal stroke, hospitalisation for unstable angina, or coronary revascularisation procedures. </p> </li> <li> <p>All‐cause mortality</p> </li> </ol> </p> </section> <section id="CD012502-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012502-list-0003"> <li> <p>Myocardial infarction (MI) (fatal and non‐fatal)</p> </li> <li> <p>Ischaemic stroke (fatal and non‐fatal)</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Coronary revascularisation</p> </li> <li> <p>Adverse events (AEs) including hepatopathy, myopathy, rhabdomyolysis, cancer, gallbladder‐related disease and discontinuation due to AEs </p> </li> <li> <p>Lipid parameters (total cholesterol, LDL‐C, HDL‐C, triglycerides): mean difference (MD) at the end of follow‐up or the change from baseline </p> </li> <li> <p>Health‐related quality of life (using any well‐validated scale)</p> </li> </ol> </p> </section> </section> </section> <section id="CD012502-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012502-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified trials through systematic searches of the following bibliographic databases on 27 June 2018. </p> <p> <ol id="CD012502-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 6 of 12, 2018) in the Cochrane Library </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 27 June 2018) </p> </li> <li> <p>Embase (Ovid, 1980 to 2018 week 26)</p> </li> <li> <p>Web of Science Core Collection (Thomson Reuters, 1900 to 27 June 2018)</p> </li> </ol> </p> <p>We adapted the preliminary search strategy for MEDLINE (Ovid) (<a href="./appendices#CD012502-sec-0125">Appendix 1</a>) for use in the other databases and we applied the Cochrane sensitivity‐maximising RCT filter (<a href="./references#CD012502-bbs2-0118" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>) to MEDLINE (Ovid) and adaptations of it to the other databases, except CENTRAL. </p> <p>We also conducted a search of <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) for relevant RCTs on 11 July 2018. </p> <p>We searched all databases from their inception to the present, and we imposed no restriction on language of publication. </p> <p>We did not perform a separate search for adverse effects of interventions used for the treatment of ezetimibe. We considered adverse effects described in included studies only. </p> </section> <section id="CD012502-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references. We contacted study authors to clarify details or obtain additional data not included in the publish reports. </p> <p>We also examined any relevant retraction statements and errata for included studies.</p> <p>In addition, we retrieved publicly‐available application materials of the IMPROVE‐IT study that were published on Food and Drug Administration (FDA) website. </p> </section> </section> <section id="CD012502-sec-0047"> <h3 class="title" id="CD012502-sec-0047">Data collection and analysis</h3> <section id="CD012502-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SZ, MT) independently screened titles and abstracts for inclusion of all the potential studies we identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. If there were any disagreements, a third review author was asked to arbitrate (PX). We retrieved the full‐text study reports/publication and two review authors (SZ, MT) independently screened the full‐text and identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, consulted a third person (PX). We identified and excluded duplicates and collate multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD012502-bbs2-0119" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6:e1000100. ">Liberati 2009</a>) and '<a href="./references#CD012502-sec-0134" title="">Characteristics of excluded studies</a>' table. </p> </section> <section id="CD012502-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data that has been piloted on at least one study in the review. Two review authors (SZ, MT) extracted study characteristics from included studies. We extracted the following study characteristics. </p> <p> <ol id="CD012502-list-0005"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, body mass index (BMI), smoking history, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (SZ, MT) independently extracted outcome data from included studies. We resolved disagreements by consensus or by involving a third person (PX). One review author (FL) transferred data into the Review Manager 5 (RevMan 5) (<a href="./references#CD012502-bbs2-0129" title="Nordic Cochrane Centre; The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre; The Cochrane Collaboration, 2014. ">RevMan 2014</a>) file. We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (PX) spot‐checked study characteristics for accuracy against the study report. </p> </section> <section id="CD012502-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SZ, FL) independently assessed the risk of bias for each included study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012502-bbs2-0112" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved any disagreements by discussion or by involving another review author (PX). We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD012502-list-0006"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias. (e.g. industry funding)</p> </li> </ol> </p> <p>We graded each potential source of bias as 'high', 'low' or 'unclear' and provided a quote from the study report together with a justification for our judgment in the 'Risk of bias' section of the <a href="./references#CD012502-sec-0133" title="">Characteristics of included studies</a> table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' section of the <a href="./references#CD012502-sec-0133" title="">Characteristics of included studies</a> table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD012502-sec-0051"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to this published protocol (<a href="./references#CD012502-bbs2-0144" title="ZhanS , XiaP , TangM , LiuF , ShuM , WuX . Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012502] ">Zhan 2017</a>) and reported any deviations from it in the '<a href="#CD012502-sec-0131">Differences between protocol and review</a>' section of the systematic review. </p> </section> </section> <section id="CD012502-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). One of the included studies (<a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>) reported hazard ratios (HRs) for subgroup analyses stratified by age, gender, statin experience and diabetes at baseline, and these HR are reported narratively in the text. We analysed continuous data as mean difference (MD) because all studies used the same scales. We entered the data presented as a scale with a consistent direction of effect. We described skewed data reported as medians and interquartile ranges (IQRs) in narrative form. </p> </section> <section id="CD012502-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>We included RCTs with parallel design. Three studies (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>) had three intervention arms. However, we only included data from two intervention arms related to this review. </p> </section> <section id="CD012502-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible. Where this were not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by a sensitivity analysis. </p> </section> <section id="CD012502-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed methodological and clinical heterogeneity with respect to the type of participants, interventions and outcomes in the included studies. We evaluated statistical heterogeneity using the Chi² test with a P value less than 0.1 indicating significant heterogeneity, and we used the I² statistic (<a href="./references#CD012502-bbs2-0111" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>) to quantify statistical heterogeneity. In cases of no heterogeneity, we performed a fixed‐effect meta‐analysis, whereas if we identified substantial heterogeneity (I² greater than 50%), we reported this finding and explored possible causes through a prespecified subgroup analysis. If the source of heterogeneity could not be explained, we considered the following options: we used a random‐effects model with appropriate cautious interpretation or provided a narrative overview and did not aggregate the studies. </p> </section> <section id="CD012502-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>We explored any possible reporting bias by assessing asymmetry in funnel plots to determine whether the studies were selectively reported (<a href="./references#CD012502-bbs2-0136" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). We constructed a funnel plot if at least 10 studies could be included. </p> </section> <section id="CD012502-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses only if the analysis was meaningful, that is, if the treatments, participants and underlying clinical question were similar enough for pooling to make sense. We used RevMan 5 (<a href="./references#CD012502-bbs2-0129" title="Nordic Cochrane Centre; The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre; The Cochrane Collaboration, 2014. ">RevMan 2014</a>) to combine the outcomes from individual trials if these were consistent on clinical grounds and if outcome data were available. In the absence of substantial heterogeneity (I² &lt; 50%) and if there were sufficient trials, we combined the results using a fixed‐effect model. If the heterogeneity was substantial, we performed a random‐effects meta‐analysis with appropriate cautious interpretation or provided a narrative overview and did not aggregate the studies (<a href="./references#CD012502-bbs2-0104" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>; <a href="./references#CD012502-bbs2-0113" title="Huedo‐MedinaTB , Sanchez‐MecaJ , Marin‐MartinezF , BotellaJ . Assessing heterogeneity in meta‐analysis: Q statistic or I2 index?. Psychological Methods2006;11(2):193‐206. ">Huedo‐Medina 2006</a>). For dichotomous outcomes, we used Mantel‐Haenszel methods to calculate the pooled RRs. We analysed continuous outcomes using an inverse variance method for pooling MDs, and had the studies used different scales, we would have used standardised mean differences (SMDs) (<a href="./references#CD012502-bbs2-0104" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). All the data are accompanied by the 95% CIs. </p> <section id="CD012502-sec-0058"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table using the following outcomes.</p> <p> <ol id="CD012502-list-0007"> <li> <p>Major adverse cardiovascular events (MACE)</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Myocardial infarction (MI) (fatal and non‐fatal)</p> </li> <li> <p>Ischaemic stroke (fatal and non‐fatal)</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>AEs (hepatopathy)</p> </li> <li> <p>AEs (myopathy)</p> </li> </ol> </p> <p>Two review authors (SZ, FL) independently graded the body of evidence using adapted decision rules. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies that contributed data to the meta‐analyses for the prespecified outcomes. We used the methods and recommendations described in Section 8.5 (<a href="./references#CD012502-bbs2-0112" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) and Chapter 12 (<a href="./references#CD012502-bbs2-0135" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> using <a href="https://gradepro.org/" target="_blank">GRADEpro GDT</a> software. The overall quality of the evidence was assessed as either high, moderate, low or very low. We justified all decisions to down‐ or up‐grade the quality of the studies using footnotes, and provided comments to aid the readers' understanding of the review where necessary. </p> </section> </section> <section id="CD012502-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses.</p> <p> <ol id="CD012502-list-0008"> <li> <p>Age (≥ 65 years versus &lt; 65 years)</p> </li> <li> <p>Sex</p> </li> <li> <p>Statin treatment prior to trial participation versus no statin treatment prior to trial participation </p> </li> <li> <p>Diabetes at baseline</p> </li> <li> <p>Duration of follow‐up ≤ 2 years and &gt; 2 years</p> </li> <li> <p>Participants with or without existing atherosclerotic cardiovascular disease (ASCVD)</p> </li> </ol> </p> <p>We used the following outcomes in the subgroup analyses:</p> <p> <ol id="CD012502-list-0009"> <li> <p>Major adverse cardiovascular events (MACEs)</p> </li> <li> <p>All‐cause mortality</p> </li> </ol> </p> <p>We used the formal test for subgroup interactions in RevMan 5 (<a href="./references#CD012502-bbs2-0129" title="Nordic Cochrane Centre; The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre; The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>However, we were only able to perform subgroup analyses based on duration of follow‐up and participants with or without existing ASCVD because data for the prespecified subgroups were unavailable. <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> reported the subgroup analysis of primary composite endpoints (MACE) by age, gender, statin experience and diabetes at baseline, so we reported these results in the text. </p> </section> <section id="CD012502-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We performed the following sensitivity analyses.</p> <p> <ol id="CD012502-list-0010"> <li> <p>A sensitivity analysis that included only studies with a low risk of bias was performed. We regarded studies as at low risk of bias if no domain was at high risk of bias and at least five domains (randomisation, allocation concealment, performance and detection biases, attrition bias) for bias assessment were judged to be low risk. </p> </li> <li> <p>The consistency in primary outcomes between different statistical models (fixed‐effect models and random‐effects models) was checked. </p> </li> <li> <p>A sensitivity analysis that excluded studies compared ezetimibe plus statins versus double‐dose statins alone. </p> </li> </ol> </p> <section id="CD012502-sec-0061"> <h5 class="title">Reaching conclusions</h5> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We avoided making recommendations for practice and in the <a href="#CD012502-sec-0121">Implications for research</a>' section, we suggest priorities for future research and outline what the remaining uncertainties are in the area. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012502-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012502-sec-0062"></div> <section id="CD012502-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD012502-sec-0064"> <h4 class="title">Results of the search</h4> <p>The search of databases retrieved 7180 records and the clinical trial registries retrieved 515 records. Two reference was identified through reference checking. After the removal of duplicates, we screened the titles and abstracts of 3823 records. Among them, 3625 records did not meet the inclusion criteria and were therefore excluded. The remaining 198 records were assessed for eligibility through a review of full text, and 63 studies (83 records) were excluded. Finally, 26 studies (108 records) were found to be eligible for inclusion. We identified three ongoing studies and four studies awaiting classification. This process is illustrated with a PRISMA flow chart (<a href="#CD012502-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012502-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012502-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012502-sec-0065"> <h4 class="title">Included studies</h4> <p>Details of the methods, participants, intervention, comparison and outcome measures for each of the studies are shown in the <a href="./references#CD012502-sec-0133" title="">Characteristics of included studies</a> table and <a href="#CD012502-tbl-0002">Table 1</a>. </p> <div class="table" id="CD012502-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of included studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Location</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Centres</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised</b> </p> <p>(intervention/control)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> (years) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical setting</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> <p>(multinational)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201/45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>primary hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/d +ezetimibe10 mg/d</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/day + placebo</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118/59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hyperlipidaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fenofibrate 160 mg˜200 mg/day + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fenofibrate 160 mg˜200 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the Netherlands (multinational)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357/363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>familial hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 80 mg/day + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 80 mg/day + placebo</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute coronary syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pitavastatin 2 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pitavastatin 2 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>869/865</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.86 (median)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute coronary syndrome and dyslipidaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pitavastatin¹ + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pitavastatin²</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> <p> (multinational)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9067/9077</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (median)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute coronary syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + ezetimibe10mg/d</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + placebo</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>stable angina pectoris</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fluvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fluvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 in total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>asymptomatic, 'statin naive' patients with maximum carotid stenosis &gt;50%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greece</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126/136</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>undergoing vascular surgery</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ezetimibe 10 mg/day + rosuvastatin 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rosuvastatin 10 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114/116</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute coronary syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74/74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary heart disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danish</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43/44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ST‐segment elevation myocardial infarction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 80 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 80 mg/day + placebo</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100/100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary heart disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin (atorvastatin 10 mg/day or rosuvastatin 2.5 mg/day) + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin(atorvastatin 20 mg/day or rosuvastatin 5 mg/day )</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute myocardial infarction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rosuvastatin 10 mg/day + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rosuvastatin 10 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin (atorvastatin 10 mg/day or pitavastatin 1 mg/day ) + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin(atorvastatin 20 mg/day or pitavastatin 2 mg/day )</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122/124</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypercholesterolemia and Coronary Artery Disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin³ + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin³</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 in total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (mean)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pravastatin 5 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pravastatin 10 mg</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148/148</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>chronic kidney disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin⁴ + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin⁴</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>high risk patiens of coronary artery disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/51</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary atherosclerotic heart disease and hyperlipidaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ezetimibe 10 mg/day + rosuvastatin 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rosuvastatin 10 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51/49</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary heart disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>peripheral arterial disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>chronic kidney disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary heart disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/day</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>¹Starting dose for pitavastatin was 2 mg, adjusted the dosage to target LDL‐C of 70 mg/dL. </p> <p>²Starting dose for pitavastatin was 2 mg, adjusted the dosage to target LDL‐C of between 90 mg/dL and 100 mg/dL. </p> <p>³Atorvastatin was increased by titration within the usual dose range with a treatment goal of LDL‐C &lt; 70 mg/dL. </p> <p>⁴The choice of statins was at the discretion of the physician.</p> </div> </div> <p>This review includes 26 studies (108 records) involving 23,499 randomised participants that were published from 2004 to 2018. Three of them were international and multi‐centre studies (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>). Seven were multi‐centre studies conducted in Japan (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>). Sixteen studies were single‐centre studies, and of these, seven were conducted in China (<a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>), three were performed in Japan (<a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>), two were conducted in the USA (<a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>), one was conducted in Greece (<a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>), one was conducted in Denmark (<a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>), one was performed in Italy (<a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>), and one was conducted in Mexico (<a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>). </p> <p>The numbers of participants randomised in each study ranged from 18 (<a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>) to 18,144 (<a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>). </p> <p>The duration of follow‐up of the included studies ranged from one to six years. Although most studies had a follow‐up of one to two years (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>), three studies had a follow‐up of more than three years (<a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>). The <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> study, which included 18,144 participants and a median follow‐up period of six years, was the largest scale study, and the <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a> study was the second largest scale study, with 1734 cases and a median follow‐up period of 3.86 years. The remaining studies were small to moderate (3720 cases, 18 to 720) and had a follow‐up period of one to two years. </p> <p>Although most of the included studies had two parallel treatment arms, three studies (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>) had three intervention arms, but we only included data from two of the three intervention arms related to this review. </p> <section id="CD012502-sec-0066"> <h5 class="title">Participants</h5> <p>The studies varied in the types of participants recruited and their levels of cardiovascular disease (CVD) risk. Fourteen studies recruited participants with existing atherosclerotic cardiovascular disease (ASCVD). Specifically, four studies (<a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>) recruited participants with acute coronary syndrome (ACS); six studies (<a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>) recruited participants with coronary heart disease; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a> recruited participants with ST‐segment elevation myocardial infarction (MI); <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a> recruited participants with acute MI; <a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> recruited participants with stable angina pectoris; and <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a> recruited participants with peripheral arterial atherosclerosis (PAD). </p> <p>Seven studies (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>) recruited participants with hypercholesterolaemia; two studies (<a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>) recruited participants with chronic kidney disease (CKD); <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a> recruited participants undergoing vascular surgery; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a> recruited participants at high risk of coronary artery disease; and <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a> recruited participants with maximum carotid stenosis &gt; 50%. </p> <p>The participants' mean age ranged from 46 years (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>) to 84 years (<a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>). Fifteen studies recruited participants with a mean age in the range of 50 to 65 years (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>), seven studies recruited older participants (mean age of at least 65 years, <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>), one study recruited younger participants (mean age under 50 years, <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>), and three studies did not specify the age of the participants (<a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>). </p> <p>The participants in 10 studies were mostly male (at least 70%) (<a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>). Thirteen of the included studies recruited equal numbers of men and women, whereas the other three studies did not state the gender of the participants (<a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>). </p> <p>Two studies only included participants with type 2 diabetes (<a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>), one study excluded participants with diabetes (<a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>), four studies did not report data on participants with diabetes (<a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>), and the remaining 19 studies included participants with diabetes, and the proportion of these participants ranged from 1.8% (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>) to 51.3% (<a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>) of the entire cohort. </p> <p>A summary of the characteristics of the participants in the included studies is shown in <a href="#CD012502-tbl-0003">Table 2</a>. </p> <div class="table" id="CD012502-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (mean ± SD)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Male%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI (mean ± SD)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes mellitus%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypertension%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>History of CHD%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>History of MI%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PAD%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stain</b> </p> <p><b>pretreatment%</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.7 ± 14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.6 ± 12.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4 ± 4.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.03</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.9 ± 9.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 ± 4.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 ± 11.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.1 ± 11.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3 ± 3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.6 ± 9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.3 ± 5.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.3 ± 11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.8 ± 5.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 ± 12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (washout)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.1 ± 2.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.5 ± 3.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66. ± 76.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.6 ± 4.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2 ± 12.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0 ± 5.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.3 ± 10.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.3/27.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.8 ± 9.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.2 ± 3.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.0 ± 2.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.2 ± 10.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.5 ± 10.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.9 ± 3.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 ± 12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.5 ± 1.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.5 ± 8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 ± 5.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.0 ± 11.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 ± 9.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.6 ± 9.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.9 ± 6.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 ± 10.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.8 ± 6.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BMI: body mass index; CHD: coronary heart disease; MI: myocardial infarction; NR: not reported; PAD: peripheral arterial disease; SD: standard deviation. </p> </div> </div> </section> <section id="CD012502-sec-0067"> <h5 class="title">Interventions and comparators</h5> <p>No study compared ezetimibe alone versus placebo. All the included studies compared ezetimibe plus other lipid‐modifying drugs versus other lipid‐modifying drugs alone or plus placebo. Only one study (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>) compared ezetimibe plus fenofibrate versus fenofibrate alone. The remaining 25 studies compared ezetimibe plus statins versus statins alone or plus placebo. The dose of ezetimibe in all studies was 10 mg/day. </p> <p>Eighteen studies used the same initial dose of statin in the intervention group and control group. Among these studies, five compared ezetimibe plus simvastatin versus simvastatin alone (<a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>) or simvastatin plus placebo (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>); seven compared ezetimibe plus atorvastatin versus atorvastatin alone (<a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>) or atorvastatin plus placebo (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>); three compared ezetimibe plus rosuvastatin versus rosuvastatin alone (<a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>); two compared ezetimibe plus pitavastatin versus pitavastatin alone (<a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>); and one compared ezetimibe plus fluvastatin versus fluvastatin alone (<a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>). </p> <p>Seven studies used the usual dose of statin plus ezetimibe compared with a double‐dose of statin. <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a> compared ezetimibe plus atorvastatin versus double‐dose atorvastatin; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a> compared ezetimibe plus simvastatin versus double‐dose simvastatin; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a> compared ezetimibe plus pitavastatin versus double‐dose pitavastatin; and <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a> compared ezetimibe plus atorvastatin or rosuvastatin versus double‐dose atorvastatin or rosuvastatin. In addition, <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a> compared ezetimibe plus atorvastatin or pitavastatin versus double‐dose atorvastatin or pitavastatin; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a> compared ezetimibe plus statin versus double‐dose statin, the choice of statins was at the discretion of the physician; and <a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> compared ezetimibe plus statin versus incremental dose of statin, but did not report which statin was used. </p> </section> <section id="CD012502-sec-0068"> <h5 class="title">Outcome</h5> <p>Five studies specified the composite of cardiovascular events as the primary outcome (<a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>), whereas five studies specified serum lipid parameters as the primary outcome (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>), and three studies specified changes in coronary intravascular ultrasonography outcome as the primary outcome (<a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>). <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a> and <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a> specified changes in carotid intima‐media thickness (cIMT) as the primary outcome and <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a> specified changes in the superficial femoral artery plaque volume as the primary outcome. <a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a> and <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a> specified the incidence of adverse events (AEs) as the primary outcome, and <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a> specified changes in kidney function (estimated glomerular filtration rate (e‐GFR)) as the primary outcome. Four studies (<a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>) did not specify the primary outcomes but evaluated the lipid levels, cIMT and adverse reactions. In addition, <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a> and <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a> also reported cardiovascular events. </p> <p>Three studies (<a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>) were only published as conference abstracts. <a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> reported the coronary plaque volume, serum lipids and cardiovascular events; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a> reported the cIMT and serum lipids; and <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a> did not report any outcome data of relevance for this review. We attempted to contact the authors for more information regarding study design and outcomes, but no contact could be established. </p> <p>For the studies that did not report outcomes of interest, we emailed the trialists to establish whether these outcomes were measured but not reported, but only Dr. Mikkel provided additional data (<a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>). No response was received from the other studies (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>). </p> <p>Among all the included studies, 10 studies specified Major adverse cardiovascular events (MACE) as an outcome (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>), but the definition of MACE was not consistent across these studies. In addition, three studies specified all‐cause mortality as an outcome (<a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>). </p> </section> <section id="CD012502-sec-0069"> <h5 class="title">Sources of funding</h5> <p>Five studies were funded by the pharmaceutical industry (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>); nine studies were funded by not‐for‐profit organisations (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>); four studies did not receive any funding (<a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>); and eight studies did not report their funding sources (<a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>). </p> </section> </section> <section id="CD012502-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We excluded 63 studies (83 references) after full‐text assessment, and detailed reasons for exclusion are provided in the <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012345.pub2/references#CD012345-sec2-0021" target="_blank">Characteristics of excluded studies</a> table. The reasons for exclusion included non‐randomised controlled trial (non‐RCT), follow‐up period shorter than 12 months, ineligible comparison, inappropriate study design and irrelevant intervention. </p> <section id="CD012502-sec-0071"> <h5 class="title">Studies awaiting classification</h5> <p>We identified four studies that await classification (<a href="./references#CD012502-bbs2-0090" title="JPRN‐UMIN000002964 . Prospective, randomized, open‐label, clinical trial comparing fibrate monotherapy and fibrate‐ezetimibe combination therapy on progression of atherosclerotic plaques, endothelial function, and markers for anti‐inflammatory properties/obesity/antioxidative properties. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002964 (date of registration 3 January 2010). ">JPRN‐UMIN000002964</a>; <a href="./references#CD012502-bbs2-0091" title="JPRN‐UMIN000011745 . Prospective, randomized, open‐label, clinical trial comparing rosuvastatin monotherapy and combination therapy with ezetimibe on progression of atherosclerotic plaques and endothelial function. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000011745 (date of registration 14 September 2013). ">JPRN‐UMIN000011745</a>; <a href="./references#CD012502-bbs2-0092" title="NCT01086020 . Atorvastatin plus Ezetimibe on coronary Plaque Progression (AEPP). clinicaltrials.gov/ct2/show/NCT01086020 (first posted 12 March 2010). ">NCT01086020</a>; <a href="./references#CD012502-bbs2-0093" title="NCT02588235 . Ezetimibe and atorvastatin Therapy on TCFA. clinicaltrials.gov/ct2/show/NCT02588235 (first posted 27 October 2015). ">NCT02588235</a>). Details of these studies are shown in the <a href="./references#CD012502-sec-0135" title="">Characteristics of studies awaiting classification</a>. These studies with an unknown recruitment status are listed on the clinical trial registries, and their completion date was more than two years ago. We contacted the authors of these for more information but did not receive a reply. </p> </section> <section id="CD012502-sec-0072"> <h5 class="title">Ongoing studies</h5> <p>We identified three ongoing studies that likely fit our inclusion criteria (<a href="./references#CD012502-bbs2-0094" title="NCT03044665 . RAndomized Comparison of efficacy and safety of lipid‐lowerING with statin monotherapy versus statin/ezetimibe combination for high‐risk cardiovascular diseases (RACING Trial). https://clinicaltrials.gov/ct2/show/NCT03044665. ">NCT03044665</a>; <a href="./references#CD012502-bbs2-0095" title="NCT03169985 . Usual dose Rosuvastatin plus EZetimibe versus high‐dose rosuvastatin on coronary atherosclerotic plaque (Rosuzet‐IVUS). clinicaltrials.gov/ct2/show/nct03169985 (first posted 30 May 2017). ">NCT03169985</a>; <a href="./references#CD012502-bbs2-0096" title="NCT03543774 . Lipid‐lowering therapies in Vietnamese Chronic Kidney Disease population (VietCKD). clinicaltrials.gov/ct2/show/NCT03543774 (first posted 1 June 2018). ">NCT03543774</a>), and the details of these studies are shown in the table titled "<a href="./references#CD012502-sec-0136" title="">Characteristics of ongoing studies</a>". </p> </section> </section> </section> <section id="CD012502-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of the included studies are detailed in the table titled "<a href="./references#CD012502-sec-0133" title="">Characteristics of included studies</a>".<br/> An overview of the review authors' judgements about each risk of bias item for each individual study and across all studies is provided in <a href="#CD012502-fig-0002">Figure 2</a> and <a href="#CD012502-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012502-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012502-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012502-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012502-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012502-sec-0074"> <h4 class="title">Allocation</h4> <p>Fourteen studies reported random sequence methods and were rated as low risk of bias (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>). We assessed 12 studies at unclear risk of bias for this domain because no information was provided in the study reports. </p> <p>Seven studies used a method for allocation concealment that was judged to be of low risk of bias (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>). We judge <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a> to be at high risk of bias for this domain because the study reported that allocation concealment was not implemented. We assessed 18 studies to be at unclear risk of bias for this domain because no information was provided in study reports. </p> </section> <section id="CD012502-sec-0075"> <h4 class="title">Blinding</h4> <p>We assessed four studies as low risk of bias regarding blinding of participants and personnel (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>). Eight studies were based on an open‐label designs and were therefore judged to be at high risk of performance bias (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>). Two studies (<a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>) reported double‐blind designs but did not use a matching placebo; thus we judged these studies to be at unclear risk of performance bias. The remaining 12 studies were assessed to be at unclear risk of bias because no information was provided. </p> <p>Detection bias was judged to be at low risk in ten studies (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>). Two studies (<a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>) were open‐label designs and did not describe the blinding of assessors; therefore we judged these to be at high risk of detection bias. The remaining 14 studies did not provide information and were judged to be at unclear risk of detection bias. </p> </section> <section id="CD012502-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition bias was judged to be at low risk in 14 studies (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>) because the dropout rate was &lt; 20% and balanced between the trial arms, number of participants that discontinued were reported and reasons were stated, and all outcomes analyses were performed by using a intention‐to‐treat principle. Three studies were judged to be at high risk of bias for this domain because the dropout rate was over 20% and did not use appropriate methods to address the missing data (<a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>). The remaining nine studies were assessed as unclear risk of bias for attrition bias because no information was provided for judgement. </p> </section> <section id="CD012502-sec-0077"> <h4 class="title">Selective reporting</h4> <p>We assessed 10 studies to be at low risk of reporting bias (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>) because they reported all prespecified outcomes in either published protocols or clinical trial registers before enrolment. We were unable to assess the reporting bias in 16 studies because the information was not available in the form of protocols or clinical trial registry entries. </p> </section> <section id="CD012502-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>Fifteen studies were judged to be at low risk of other biases (mainly based on providing funding details and declaring any conflict of interest by the authors) (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>). </p> <p>We judged three studies (<a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>) to be at high risk of other bias because they were only published as conference abstracts, and not publishing complete results might lead to a bias. The remaining eight studies were judged to be at an unclear risk of bias because there was insufficient information to make a judgement. </p> </section> </section> <section id="CD012502-sec-0079"> <h3 class="title" id="CD012502-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD012502-tbl-0001"><b>Summary of findings for the main comparison</b> Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events</a> </p> <p>We included 26 studies that involved a total of 23,499 participants and assessed ezetimibe combined with other lipid‐modifying drugs versus other lipid‐modifying drugs alone or plus placebo. The main outcomes for this comparison are presented in <a href="./full#CD012502-tbl-0001">summary of findings Table for the main comparison</a>. The findings from this comparison were driven by <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>. Three studies (<a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>) did not contribute any outcome data of interest for this review. </p> <section id="CD012502-sec-0080"> <h4 class="title">Primary outcome</h4> <section id="CD012502-sec-0081"> <h5 class="title">Major adverse cardiovascular events (MACEs)</h5> <p>Twelve studies provided data on MACE (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>), but the definitions of MACE in some studies were not completely consistent with this review. Of these studies, <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a> reported that no serious cardiovascular event occurred, and <a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> reported that three cardiovascular events occurred in the ezetimibe group and seven cardiovascular events occurred in the control group. However, because their definition of cardiovascular events was unclear and we were unable to contact the researchers for further information, we did not include these two studies in the meta‐analysis. </p> <p>We included data from 10 studies in the meta‐analysis (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>). The analysis performed with a fixed‐effect model revealed that the ezetimibe group had a lower risk of MACE than the control group (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.90 to 0.98; I² = 0%; a decrease from 284/1000 to 267/1000, 95% 256 to 278; participants = 21,727; studies = 10; moderate‐quality evidence; <a href="./references#CD012502-fig-0010" title="">Analysis 1.1</a>). It should be noted that the pooled MACE result in our review was likely influenced by <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> results, which were driven by differences in non‐fatal MI, non‐fatal stroke and urgent coronary revascularisations. </p> <p>The funnel plot (<a href="#CD012502-fig-0004">Figure 4</a>) did not indicate a strong possibility of publication bias. </p> <div class="figure" id="CD012502-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.1 MACE (subgroup analysis: duration of follow‐up)." data-id="CD012502-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.1 MACE (subgroup analysis: duration of follow‐up). </p> </div> </div> </div> </section> <section id="CD012502-sec-0082"> <h5 class="title">All‐cause mortality</h5> <p>Eleven studies provided data on death from any cause (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a> ; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>). Of these, two studies reported that no deaths occurred (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>), and one study (<a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>) reported the total deaths but did not provide data by treatment arm. </p> <p>We included data from eight studies in the meta‐analysis (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a><a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>). When the data were pooled with a fixed‐effect model, there was little or no difference in the reduction of all‐cause mortality between the groups (RR 0.98, 95% CI 0.91 to 1.05; I² = 0%; participants = 21,222; studies = 8; high‐quality evidence; <a href="./references#CD012502-fig-0015" title="">Analysis 1.6</a>). </p> </section> </section> <section id="CD012502-sec-0083"> <h4 class="title">Secondary outcomes</h4> <section id="CD012502-sec-0084"> <h5 class="title">Myocardial infarction (MI) (fatal and non‐fatal)</h5> <p>Data on MI were provided in nine studies (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>), and two of these reported that no MI events occurred (<a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>). <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a> only provided data on MI that occurred during the follow‐up period of 1 to 12 months (no events occurred in the intervention group, three fatal MI and one nonfatal MI occurred in the control group) but did not provide data on MI that occurred within 30 days of follow‐up. </p> <p>We included data from six studies that reported non‐fatal MI in the meta‐analysis (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>). The analysis performed using a fixed‐effect model showed that the ezetimibe group had a lower risk of non‐fatal MI than the control group (RR 0.88, 95% CI 0.81 to 0.95; I² = 0%; a decrease from 105/1000 to 92/1000, 95% CI 85 to 100; participants = 21,145; studies = 6; moderate‐quality evidence; <a href="./references#CD012502-fig-0020" title="">Analysis 1.11</a>). <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a> and <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a> reported that fatal MI events did not occur. </p> <p>In addition, <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> with 18,044 participants also provided hazard ratios (HR) on any MI (HR 0.87, 95% CI 0.80 to 0.95) and fatal MI (HR 0.84, 95% CI 0.55 to 0.1.27). </p> </section> <section id="CD012502-sec-0085"> <h5 class="title">Stroke (fatal and non‐fatal)</h5> <p>Eight studies provided data on stroke (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>). Among these, <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a> reported that no events of stroke occurred. <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a> only provided data on ischaemic stroke that occurred during the follow‐up period of one to 12 months (one event in each group), but did not provide data on stroke events that occurred within 30 days of follow‐up. </p> <p>We included data from six studies that reported non‐fatal stroke in the meta‐analysis (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>). When the data were pooled with a fixed‐effect model, the ezetimibe group had a lower risk of non‐fatal stroke than the control group (RR 0.83, 95% CI 0.71 to 0.97; I² = 0%; a decrease 32/1000 to 27/1000, 95% CI 23 to 31; participants = 21,205; studies = 6; moderate‐quality evidence; <a href="./references#CD012502-fig-0023" title="">Analysis 1.14</a>). <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a> and <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a> reported that fatal stroke events did not occur. </p> <p>In addition, <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> with 18,044 participants also provided hazard ratios on any stroke (HR 0.86, 95% CI 0.73 to 1.00), ischaemic stroke (HR 0.79, 95% CI 0.67 to 0.94), hemorrhagic stroke (HR 1.38, 95% CI 0.93 to 2.04), and fatal stroke (HR 1.22, 95% CI 0.81 to 1.82). </p> </section> <section id="CD012502-sec-0086"> <h5 class="title">Cardiovascular mortality</h5> <p>Data on death from cardiovascular causes were available in 11 studies (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>). Four of these reported that no cardiovascular deaths occurred (<a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>), and one study reported total cardiac deaths but did not provide data by treatment arm (<a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>). </p> <p>We included data from six studies in the meta‐analysis (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>). The analysis using a fixed‐effect model found little or no difference in the reduction of cardiovascular mortality between the groups (RR 1.00, 95% CI 0.89 to 1.12; I² = 0%; participants = 19,457; studies = 6; moderate‐quality evidence; <a href="./references#CD012502-fig-0026" title="">Analysis 1.17</a>). </p> </section> <section id="CD012502-sec-0087"> <h5 class="title">Coronary revascularisation</h5> <p>Seven studies provided data on coronary revascularisation (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>). When the data were pooled with a fixed‐effect model, the rate of coronary revascularisation was slightly lower in the ezetimibe group compared with the control group (RR 0.94, 95% CI 0.89 to 0.99; I² = 0%; a decrease from 196/1000 to 184/1000, 95% CI 175 to 194; participants = 21,323; studies = 7; <a href="./references#CD012502-fig-0029" title="">Analysis 1.20</a>). </p> <p>However, a sensitivity analysis that included only studies at low overall risk of bias revealed little or no difference in coronary revascularisation rate between the groups (RR 0.94, 95% CI 0.89 to 1.00; I² = 0%; participants = 18,864; studies = 2; <a href="./references#CD012502-fig-0030" title="">Analysis 1.21</a>). </p> </section> <section id="CD012502-sec-0088"> <h5 class="title">Adverse events (AEs)</h5> <p>All the included studies except six provided data on AEs. Pooling the total number of AEs in all the studies was not feasible due to heterogeneity of the definition of AEs and because not all of the studies reported the total number of AEs. The individual studies included in this review showed no difference in AEs between the ezetimibe group and the control group. The following specific AEs, including hepatopathy, myopathy, rhabdomyolysis, cancer, gallbladder‐related disease and discontinuation due to AEs were analysed: </p> <section id="CD012502-sec-0089"> <h6 class="title">Hepatopathy (liver injury)</h6> <p>In this review, hepatopathy was defined as the hepatic transaminase (alanine aminotransferase (ALT) or aspartate aminotransferase (AST), or both) levels exceeded three times the upper limit of normal rang (≥ 3 x ULN (upper limit of normal)) in this review. </p> <p>Sixteen of the included studies evaluated the hepatic enzyme levels during the study periods (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>). Among these, 10 studies reported no occurrence in the levels of ALT or AST, or both values being more than or equal 3 x ULN (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>). <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a> reported data on ALT or AST greater than 2 x ULN. <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a> reported data on abnormal ALT/AST levels, but did not specify the definition of liver enzyme abnormalities. </p> <p>We included data from four studies in the meta‐analysis (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a><a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>). The analysis of pooled data with a fixed‐effect model revealed no evidence for a difference in the risk of hepatopathy between the groups (RR 1.14, 95% CI 0.96 to 1.35; I² = 0%; participants = 20,687; studies = 4; low‐quality evidence; <a href="./references#CD012502-fig-0032" title="">Analysis 1.23</a>). </p> </section> <section id="CD012502-sec-0090"> <h6 class="title">Myopathy</h6> <p>Myopathy was defined as a creatine kinase (CK) level ≥ 10 x ULN with associated muscle symptoms. </p> <p>Sixteen studies evaluated myopathy and the CK level during the study period (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>), and 13 of these studies reported that none of the participants in either group developed a CK level ≥ 10 x ULN (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>; <a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a>). </p> <p>We included data from three studies in the meta‐analysis (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>). When the data were pooled with a fixed‐effect model, no evidence of a difference in the risk of myopathy was found between the groups (RR 1.31, 95% CI 0.72 to 2.38; I² = 0%; participants = 20,581; studies = 3; very low‐quality evidence; <a href="./references#CD012502-fig-0034" title="">Analysis 1.25</a>). </p> </section> <section id="CD012502-sec-0091"> <h6 class="title">Rhabdomyolysis</h6> <p>Four studies reported data on rhabdomyolysis (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>), and two of these studies reported no occurrence of rhabdomyolysis events (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>). We included data from two studies in the meta‐analysis (<a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>), and the analysis of pooled data with a fixed‐effect model revealed no evidence for a difference in risk of rhabdomyolysis between the groups (RR 0.79, 95% CI 0.40 to 1.55; I² = 0%; participants = 19,865; studies = 2; <a href="./references#CD012502-fig-0036" title="">Analysis 1.27</a>). </p> </section> <section id="CD012502-sec-0092"> <h6 class="title">Cancer</h6> <p>In this review, the term cancer includes any new, relapsing, or progressing cancer. Six of the included studies reported data on cancer rates (<a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>), and one of the studies reported three cases of cancer, but did not provide data by treatment arm (<a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>). We included data from five studies in the meta‐analysis (<a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>), and when the data were pooled with a fixed‐effect model, little or no difference in cancer rates was detected between the groups (RR 1.01, 95% CI 0.92 to 1.11; I² = 0%; participants = 20,455; studies = 5; <a href="./references#CD012502-fig-0038" title="">Analysis 1.29</a>). </p> </section> <section id="CD012502-sec-0093"> <h6 class="title">Gallbladder‐related disease</h6> <p>Three studies reported data on gallbladder‐related disease (<a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>). The analysis performed with a fixed‐effect model showed that there seemed to be some weak evidence of a small reduction in gallbladder‐related disease between groups (RR 0.88, 95% CI 0.75 to 1.03; I² = 0%; participants = 20,024; studies = 3; <a href="./references#CD012502-fig-0041" title="">Analysis 1.32</a>). </p> </section> <section id="CD012502-sec-0094"> <h6 class="title">Discontinuation due to adverse events</h6> <p>Twelve studies reported data on discontinuation due to AEs (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>), and two of these studies reported no discontinuation due to AEs (<a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a>). </p> <p>We included data from 10 studies in the meta‐analysis (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>; <a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>). When the data were pooled with a fixed‐effect model, no evidence for a difference in the risk of discontinuation due to AEs between the groups was found (RR 0.91, 95% CI 0.75 to 1.09; I² = 0%; participants = 21,746; studies = 10; <a href="./references#CD012502-fig-0043" title="">Analysis 1.34</a>). </p> <p>The funnel plot (<a href="#CD012502-fig-0005">Figure 5</a>) did not indicate a strong possibility of publication bias. </p> <div class="figure" id="CD012502-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.34 Discontinuation due to adverse event." data-id="CD012502-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.34 Discontinuation due to adverse event. </p> </div> </div> </div> </section> </section> <section id="CD012502-sec-0095"> <h5 class="title">Lipid parameters</h5> <p>The lipid‐related data provided in the included studies are presented in a separate table (<a href="#CD012502-tbl-0004">Table 3</a>). </p> <div class="table" id="CD012502-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of changes in lipid parameters</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> <p>　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Intervetion or control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>LDL‐C (mean ± SD, mg/dL</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>TC (mean ± SD, mg/dL)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>HDL‐C (mean ± SD, mg/dL</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>TG (mean ± SD, mg/dL)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>end</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%change from baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>end</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%change from baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>end</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%change from baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>end</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%change from baseline</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐48.4 ± 18.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐35.4 ± 14.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 ± 13.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):–29.6 (–40.3 to ‐15.1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐38.6 ± 12.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐27.5 ±10.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 ± 3.13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):–16.9 (–30.7 to 5.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 ± 27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 ± 26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−28.9 ± 15.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263 ± 30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197 ± 28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−24.2 ± 10.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 ± 10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 ± 13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3 ± 17.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266 ± 77</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 ± 74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−44.9 ± 27.3</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 ± 31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 ± 29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−17.3 ± 14.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 ± 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 ± 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−14.8 ± 11.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ± 10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 ± 14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2 ± 23.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266 ± 106</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 ± 93</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−31.8 ± 45.6</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319.0 ± 65.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141.3 ± 52.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐55.6 ± 17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400.0 ± 67.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217.3 ± 56.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐45.3 ±15.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.7 ±11.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.9 ± 12.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 ±18.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):157(113 to 217)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):108 (82 to 148)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):‐29.8(‐43.5 to 11.5)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317.8 ± 66.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192.7 ± 60.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐39.1 ± 17.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400.0 ± 68.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270.6 ± 61.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐31.9 ±15.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.4 ±13.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.7 ± 14.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8 ±17.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):160 (114 to 227)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):120(89 to 164)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):‐23.2(‐37.0 to 1.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123±32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64±18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 ± 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 ± 20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ±14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 ± 12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 ± 64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 ± 53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126±33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87±21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 ± 37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 ± 29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ±11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 ±15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 ± 52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129 ± 77</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134.8 ± 29.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.3 ± 24.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135.6 ± 30.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.5 ± 21.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I<a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:93.8; median(25th, 75th):95.0(79.0, 110.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:53.2; median(25th, 75th):50.0 (39.0, 62.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:162.7; median(25th, 75th):162.4 (144.0, 181.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:125.8; median(25th, 75th):121.0 (107.0, 139.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:42.1; median(25th, 75th):40.0 (33.0, 49.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:48.7; median(25th, 75th):47.0 (40.0, 56.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:137.6; median (25th, 75th):120.0 (85.0, 172.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:120.4; median (25th, 75th):104.0 (77.0, 143.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:93.8; median(25th, 75th):95.0(79.0, 110.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:69.9; median(25th, 75th): 67.0 (55.0, 81.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:162.6; median(25th, 75th):162.4 (144.0, 181.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:145.1; median(25th, 75th):142.0 (126.0, 160.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:42.2; median(25th, 75th):40.0 (33.0, 49.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:48.1; median(25th, 75th):46.0 (39.0, 55.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:137.5; median (25th, 75th):121.0 (85.0, 172.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:137.1; median (25th, 75th):116.0 (84.0, 165.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 ± 27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 ± 18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 ± 27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 ± 16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 ± 21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 ± 29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐30.0 ± 15.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249 ± 30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 ± 37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐21.6±11.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54±12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 ±11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 ± 14.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):144(78 to 218)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):121(88 to 180)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median(IQR):‐16.0(‐31.9 to 10.5)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 ± 20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 ± 23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐20.8 ± 13.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242 ± 26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207 ± 26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐14±8.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 ±16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 ±15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 ± 13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):149(103 to 213)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):152(86 to 215)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):2.7(‐29.9 to 43.1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148.2 ± 58.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.9 ± 31.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243.3 ± 63.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154.1 ± 35.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.9 ±12.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.7 ±9.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 ± 54.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.2 ± 31.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239.3 ± 63.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167.6 ± 36.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.3 ±11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.7 ±10.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.1 ± 23.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.4 ± 23.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.4 ± 11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.4 ±15.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132.9 ± 88.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124.0 ± 79.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.9 ± 30.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1 ± 27.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.3±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.4 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141.7 ± 132.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115.1 ± 79.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126.4 ± 14.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.3 ± 20.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222.4 ± 61.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191.4 ± 55.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.2 ±14.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.6 ± 8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201.9 ± 42.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157.7 ± 56.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130.0 ± 17.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106.3 ± 22.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227.4 ± 54.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199.5 ± 51.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6 ±17.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.8 ± 15.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208.1 ± 56.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157.7 ± 39.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138.0 ± 14.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.0 ± 22.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227.3 ± 56.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195.6 ± 57.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.2 ±15.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4 ±8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219.7 ± 39.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187.0 ± 42.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136.1 ± 17.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101.7 ± 21.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231.2 ± 56.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204.1 ± 56.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.0 ±17.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.6 ± 17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226.8 ± 56.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200.2 ± 56.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143.1 ± 27.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1 ± 30.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐62.0 ± 19.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204.9 ± 34.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112.1 ± 38.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐46.8±16.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6 ± 25.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158.5 ± 34.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3 ±19.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐52.4 ± 10.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220.4 ± 38.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135.3 ± 27.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐38.9±9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1 ± 18.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119.9 ± 22.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.1 ± 20.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193.8 ± 26.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162.9 ± 28.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.4± 11.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.5 ±12.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):139.0(92.0 to 197.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):127.5(98.3 to 181.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.3 ± 23.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.8 ± 21.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189.8 ± 24.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.9 ± 25.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.3 ± 12.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.9 ± 13.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):131(76.0 to 167.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):124.5(87.3 to 155.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116.0 ± 37.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.0 ± 16.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175.9 ± 58.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.0 ± 38.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.2 ± 10.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.5 ± 21.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170.1 ± 101.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.7 ± 47.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113.3 ± 39.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.6 ± 19.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165.5 ± 49.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117.2 ± 24.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.0 ± 8.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.5 ± 16.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156.8 ± 92.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123.1 ± 95.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 ± 21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.8 ± 19.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐28.3 ± 20.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211 ± 29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.3 ± 25.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐16.7±14.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.7 ± 15.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.7 ± 12.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 ± 95</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153.2 ± 73.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 ± 24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114.7 ± 21.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.19 ± 20.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 ± 27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198.5 ± 23.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.6±14.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.7 ± 9.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.3 ± 8.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 ± 88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160.2 ± 73.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.8 ± 25.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.2 ± 16.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐40 ± 18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177.3 ± 32.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129.4 ± 22.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐25±17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.1 ± 9.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6 ± 11.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 ± 26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):114 median(IQR):(81 to 158)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):92 (76 to 120)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):–14 (–33 to 18)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108.3 ± 26.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3 ± 20.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐29 ± 24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172.7 ± 32.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138.7 ± 26.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐18±18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0 ±10.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.3 ± 11.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 ± 25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):116 (92 to 159)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):111 (87 to 139)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):–9 (–33 to 25)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 ± 39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 ± 31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 ± 40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 ± 28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ± 11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ± 11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 ± 82</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 ± 90</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 ± 33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ± 37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215 ± 38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 ± 24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ± 9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ±10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198 ± 86</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 ± 79</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140.0 ± 45.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.0 ± 32.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218.4 ± 95.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124.1 ± 31.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.7 ± 8.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.7 ± 15.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.5 ± 59.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105.4 ± 28.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134.5 ± 48.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5 ± 30.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215.7 ± 99.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155.4 ± 35.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.7 ± 8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.3 ± 18.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.5 ± 57.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155.9 ± 33.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136.5 ± 33.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 ± 16.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203.4 ± 25.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117.9 ± 23.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170.1 ±16.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116.0 ± 17.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133.4 ±29.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.9 ± 24.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204.2 ± 26.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172.5 ± 24.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169.2 ± 18.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156.8 ± 48.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 ± 9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 ± 42.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 ± 10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136 ± 50.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 ± 4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ± 12.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 ± 21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 ± 84.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 ± 10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 ± 44.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 ± 11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 ± 48.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ± 4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 ± 16.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 ± 47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 ± 120.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149.3 ± 24.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.5 ± 21.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210.0 ± 35.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139.6 ±16.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.5±13.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.7 ± 8.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287.0 ± 70.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171.0 ± 46.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148.1 ±0.84</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114.1 ± 21.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211.1 ± 36.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172.9 ± 26.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.9±10.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.6 ± 7.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281.7 ± 73.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215.2 ± 65.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Four studies did not provide lipids data; IQR: interquartile range; NR: not reported; SD: standard deviation. </p> </div> </div> <p>All the studies except <a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a> measured lipids, and three studies measured lipids but did not provide any useable data that could be included in our meta‐analyses (<a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a>). Two studies only provided data on LDL‐C (<a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>). One study (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>) provided lipid data; only mean values without standard deviations (SDs) were provided; thus this study could not be included in the meta‐analysis. <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> performed a follow‐up for six years, but lipid data were only obtained at baseline and at the one‐year follow‐up time point, and these data were reported as the means, medians and interquartile ranges (IQRs). Because the median and mean values of the cholesterol were quite close, indicating the data were only slightly skewed, we calculated SDs from IQRs for the meta‐analyses. </p> <section id="CD012502-sec-0096"> <h6 class="title">Low‐density lipoprotein cholesterol (LDL‐C)</h6> <p>Twenty‐one studies provided data on LDL‐C at baseline and during follow‐up. Meta‐analysis using final follow‐up data suggested that the addition of ezetimibe reduced LDL‐C level, but the data were heterogeneous (MD ‐16.79 mg/dL, 95% CI ‐17.36 to ‐16.23; I² = 84%; participants = 17,854; studies = 21; <a href="./references#CD012502-fig-0046" title="">Analysis 1.37</a> ). This substantial heterogeneity might be due to differences in the lipid levels at baseline, type of disease, lengths of follow‐up, and risk of bias among the various studies. The funnel plot (<a href="#CD012502-fig-0006">Figure 6</a>) did not indicate a strong possibility of publication bias. </p> <div class="figure" id="CD012502-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.37 LDL‐C (end of follow up)." data-id="CD012502-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.37 LDL‐C (end of follow up). </p> </div> </div> </div> <p>One study (<a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>) provided LDL‐C data without variance information (conference abstracts) and could thus not be included in the meta‐analysis. This study also reported that the low‐dose pravastatin plus ezetimibe group had significantly decreased LDL‐C levels compared with the standard‐dose pravastatin group. </p> </section> <section id="CD012502-sec-0097"> <h6 class="title">Total cholesterol (TC)</h6> <p>Eighteen studies provided data on TC at baseline and follow‐up. A meta‐analysis using final follow‐up data suggested that the addition of ezetimibe reduced the TC level, but the data were heterogeneous (MD ‐19.70 mg/dL, 95% CI ‐20.48 to ‐18.92; I² = 89%; participants = 16,330; studies = 18; <a href="./references#CD012502-fig-0049" title="">Analysis 1.40</a>). This substantial heterogeneity might be due to differences in the lipid levels at baseline, type of disease, lengths of follow‐up, and risk of bias among the various studies. The funnel plot (<a href="#CD012502-fig-0007">Figure 7</a>) did not indicate a strong possibility of publication bias. </p> <div class="figure" id="CD012502-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.40 TC (end of follow up)." data-id="CD012502-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.40 TC (end of follow up). </p> </div> </div> </div> </section> <section id="CD012502-sec-0098"> <h6 class="title">High‐density cholesterol (HDL‐C)</h6> <p>Eighteen studies provided data on HDL‐C at baseline and follow‐up. A meta‐analysis using final follow‐up data suggested that the addition of ezetimibe increased the HDL‐C level (MD 0.66 mg/dL, 95% CI 0.30 to 1.03; I² = 0%; participants = 16,434; studies = 18; <a href="./references#CD012502-fig-0052" title="">Analysis 1.43</a>). The funnel plot (<a href="#CD012502-fig-0008">Figure 8</a>) did not indicate a strong possibility of publication bias. </p> <div class="figure" id="CD012502-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.43 HDL‐C (end of follow up)." data-id="CD012502-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.43 HDL‐C (end of follow up). </p> </div> </div> </div> </section> <section id="CD012502-sec-0099"> <h6 class="title">Triglycerides (TG)</h6> <p>Twelve studies provided data on TG at baseline and follow‐up. A meta‐analysis using final follow‐up data suggested that supplementation with ezetimibe resulted in a reduced TG level, but the data were heterogeneous (MD ‐27.58, 95% CI ‐33.67 to ‐21.49; I² = 74%; participants = 1253; studies = 12; <a href="./references#CD012502-fig-0055" title="">Analysis 1.46</a>). This substantial heterogeneity might be due to differences in the lipid levels at baseline, type of disease, lengths of follow‐up, and risk of bias among the various studies.The funnel plot (<a href="#CD012502-fig-0009">Figure 9</a>) did not indicate a strong possibility of publication bias. </p> <div class="figure" id="CD012502-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.46 TG (end of follow up)." data-id="CD012502-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.46 TG (end of follow up). </p> </div> </div> </div> <p>Two studies (<a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a>; <a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>) provided only mean values without SDs. Five studies (<a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>; <a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>) provided the results as medians and IQRs, and among these, <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> provided mean and median values, but the data were strongly skewed (mean = 137.6, median = 120.0). The other four studies did not provide the mean values, and a result, it is not possible to compare these data with the medians. Therefore, we removed these studies from the meta‐analyses, and present them in <a href="#CD012502-tbl-0004">Table 3</a>. </p> </section> </section> <section id="CD012502-sec-0100"> <h5 class="title">Health‐related quality of life</h5> <p>None of the included studies reported information about quality of life.</p> </section> </section> <section id="CD012502-sec-0101"> <h4 class="title">Subgroup analysis</h4> <p>We were unable to perform a subgroup analysis by age, sex, statin experience and diabetes at baseline for primary outcomes due to data being unavailable and differences in outcome reporting. However, <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> performed subgroup analysis of primary composite endpoints (cardiovascular death, nonfatal MI, documented unstable angina requiring admission to the hospital, coronary revascularisation with percutaneous coronary intervention (PCI) or : coronary artery bypass grafting (CABG) at least 30 days after randomisation, and non‐fatal stroke) by age, sex, statin experience and diabetes at baseline, and these results are reported in a narrative form. </p> <section id="CD012502-sec-0102"> <h5 class="title">Age</h5> <p>The subgroup analysis performed in the <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> study stratified by different ages showed that older patients tended to have better outcomes (&lt; 65 versus ≥ 65 years). Patients who were ≥ 65 years had a hazard ratio (HR) = 0.89 ( 95% CI 0.82 to 0.96), whereas patients &lt; 65 years had an HR = 0.98 ( 95% CI 0.90 to 1.05) (interaction P = 0.098). An analysis of other age groups (age &lt; 75 years versus ≥ 75 years) showed that patients who were ≥ 75 years had a lower HR estimate for the primary composite endpoint (0.80 (95% CI 0.70 to 0.90)) than patients who were &lt; 75 years of age (0.97 (95% CI 0.92 to 1.03), interaction P = 0.005). </p> </section> <section id="CD012502-sec-0103"> <h5 class="title">Sex</h5> <p>The <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> subgroup analyses of different sexes found no sex‐related difference in the HR ratio for the primary composite endpoint. The HR for men was 0.95 (95% CI 0.90 to 1.01), and that for women was 0.89 (95% CI 0.79 to 0.99). No evidence of an interaction between sex and outcome was found (P = 0.267). </p> </section> <section id="CD012502-sec-0104"> <h5 class="title">Statin treatment versus no statin treatment prior to trial participation</h5> <p>The subgroup analyses performed in the <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> study to investigate statin treatment prior to trial participation found no difference in the HR for the primary composite endpoint based on statin experience. People who had previously received statin treatment had an HR of 0.91 (95% CI 0.84 to 0.99), and those who had not been previously administered a statin treatment had an HR of 0.95 (95% CI 0.89 to 1.02). The findings revealed no evidence of an interaction between administration of a previous statin treatment and outcome (P = 0.414). </p> </section> <section id="CD012502-sec-0105"> <h5 class="title">Diabetes at baseline</h5> <p>In the <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> subgroup analyses of diabetes at baseline, patients with diabetes had an HR = 0.86 (95% CI 0.78 to 0.94) with an interaction P = 0.023. Among the 73% of trial participants who were non‐diabetic at baseline, the HR was 0.98 (95% CI 0.92 to 1.04). </p> </section> <section id="CD012502-sec-0106"> <h5 class="title">Duration of follow‐up</h5> <p>We performed a subgroup analysis of the follow‐up duration to assess the short‐term (≤ 2 years) and long‐term (&gt; 2 years) effects on primary outcomes. </p> <p>The subgroup analyses showed no difference in MACE between the long‐term studies (&gt; 2 years: RR 0.94, 95% CI 0.90 to 0.98, I² = 0%; participants = 19,865; studies = 2) and short‐term studies (≤ 2 years: RR 1.03, 95% CI 0.79 to 1.35, I² = 0%; participants = 1862; studies = 8) (test for subgroup differences (P = 0.50), <a href="./references#CD012502-fig-0010" title="">Analysis 1.1</a>). </p> <p>The subgroup analyses also revealed no difference in all‐cause mortality between the long‐term studies (&gt; 2 years: RR 0.97, 95% CI 0.91 to 1.05, I² = 68%; participants = 19,865; studies = 2 ) and short‐term studies (≤ 2 years: RR 1.35, 95% CI 0.61 to 3.00, I² = 0%; participants = 1357; studies = 6) (test for subgroup differences (P = 0.43), <a href="./references#CD012502-fig-0015" title="">Analysis 1.6</a>). </p> </section> <section id="CD012502-sec-0107"> <h5 class="title">Participants with versus without existing atherosclerotic cardiovascular disease (ASCVD)</h5> <p>Of the studies included in the primary outcome analysis, eight included participants with ASCVD (<a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a>; <a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a>; <a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>), and two studies (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a>) included participants with combined hyperlipidaemia and familial hyperlipidaemia, respectively, who had a lower proportion of cardiovascular disease (5.03% and 5.6%, respectively). The latter two studies were thus classified as studies that included participants without ASCVD. In another study (<a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a>), 49.2% of the participants had coronary heart disease; therefore, this study could not be classified as either a study with ASCVD or a study with participants without ASCVD and was excluded from this subgroup analysis. </p> <p>The subgroup analysis revealed no evidence of a difference in MACE between the participants with ASCVD (RR 0.94, 95% CI 0.90 to 0.98; I² = 0%; participants = 20,745; studies = 8) and participants without ASCVD (RR 1.45, 95% CI 0.56 to 3.77; participants = 720; studies = 1) (test for subgroup differences (P = 0.37), <a href="./references#CD012502-fig-0011" title="">Analysis 1.2</a>). The confidence interval was very wide, and a comparatively fewer number of individuals were included in the subgroup of participants without ASCVD. </p> <p>The subgroup analysis showed no evidence of a different in all‐cause mortality between the participants with ASCVD (RR 0.98, 95% CI 0.91 to 1.05; I² = 6%; participants = 20,343; studies = 6) and participants without ASCVD (RR 0.78, 95% CI 0.16 to 3.89; I² = 35%; participants = 879; studies = 2) (test for subgroup difference (P = 0.78) <a href="./references#CD012502-fig-0016" title="">Analysis 1.7</a>). The confidence interval was very wide, and a comparatively fewer people in the subgroup of participants without ASCVD. </p> </section> </section> <section id="CD012502-sec-0108"> <h4 class="title">Sensitivity analysis</h4> <section id="CD012502-sec-0109"> <h5 class="title">Inclusion of only studies at a low risk of bias</h5> <p>We performed a sensitivity analysis by only including studies assessed at low risk of bias. None of the estimates for most outcomes were significantly changed, except for coronary revascularisation, for which no difference between the groups was observed (<a href="./references#CD012502-fig-0012" title="">Analysis 1.3</a>; <a href="./references#CD012502-fig-0017" title="">Analysis 1.8</a>; <a href="./references#CD012502-fig-0021" title="">Analysis 1.12</a>; <a href="./references#CD012502-fig-0024" title="">Analysis 1.15</a>; <a href="./references#CD012502-fig-0027" title="">Analysis 1.18</a>; <a href="./references#CD012502-fig-0030" title="">Analysis 1.21</a>; <a href="./references#CD012502-fig-0033" title="">Analysis 1.24</a>; <a href="./references#CD012502-fig-0035" title="">Analysis 1.26</a>; <a href="./references#CD012502-fig-0037" title="">Analysis 1.28</a>; <a href="./references#CD012502-fig-0039" title="">Analysis 1.30</a>; <a href="./references#CD012502-fig-0042" title="">Analysis 1.33</a>; <a href="./references#CD012502-fig-0044" title="">Analysis 1.35</a>). </p> </section> <section id="CD012502-sec-0110"> <h5 class="title">Use of different statistical models (fixed‐effect models and random‐effects models)</h5> <p>Another meta‐analyses using a random‐effects model showed that the results of the primary outcomes were consistent with the results obtained using a fixed‐effect model (<a href="./references#CD012502-fig-0013" title="">Analysis 1.4</a>; <a href="./references#CD012502-fig-0018" title="">Analysis 1.9</a>). </p> </section> <section id="CD012502-sec-0111"> <h5 class="title">Excluding studies with serious missing data</h5> <p>We explored the impact of including studies with missing data in the overall assessment of results through a sensitivity analysis. Five studies (<a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a>; <a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>; <a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a>) had a proportion of missing data more than 20% for lipid outcomes and did not use appropriate methods to address the missing data, which were considered to introduce serious bias. The sensitivity analysis performed without these studies suggested little change in the overall results (<a href="./references#CD012502-fig-0048" title="">Analysis 1.39</a>; <a href="./references#CD012502-fig-0051" title="">Analysis 1.42</a>; <a href="./references#CD012502-fig-0054" title="">Analysis 1.45</a>; <a href="./references#CD012502-fig-0057" title="">Analysis 1.48</a>). </p> </section> <section id="CD012502-sec-0112"> <h5 class="title">Excluding studies compared ezetimibe plus statins versus double‐dose statins alone</h5> <p>We performed a sensitivity analysis by excluding studies that compared ezetimibe plus statins versus double‐dose statins alone (<a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a>; <a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a>; <a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a>; <a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a>; <a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a>; <a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a>; <a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a>). The sensitivity analysis performed without these studies suggested little change in the overall results (<a href="./references#CD012502-fig-0014" title="">Analysis 1.5</a>; <a href="./references#CD012502-fig-0019" title="">Analysis 1.10</a>; <a href="./references#CD012502-fig-0022" title="">Analysis 1.13</a>; <a href="./references#CD012502-fig-0025" title="">Analysis 1.16</a>; <a href="./references#CD012502-fig-0028" title="">Analysis 1.19</a>; <a href="./references#CD012502-fig-0031" title="">Analysis 1.22</a>; <a href="./references#CD012502-fig-0040" title="">Analysis 1.31</a>; <a href="./references#CD012502-fig-0045" title="">Analysis 1.36</a>; <a href="./references#CD012502-fig-0047" title="">Analysis 1.38</a>; <a href="./references#CD012502-fig-0050" title="">Analysis 1.41</a>; <a href="./references#CD012502-fig-0053" title="">Analysis 1.44</a>; <a href="./references#CD012502-fig-0056" title="">Analysis 1.47</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012502-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012502-sec-0113">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012502-sec-0169">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012502-sec-0113"></div> <section id="CD012502-sec-0114"> <h3 class="title" id="CD012502-sec-0114">Summary of main results</h3> <p>This review included 26 RCTs with 23,499 randomised participants. We identified three ongoing trials with treatment arms that included the interventions assessed in this review. A further four studies await assessment. </p> <p>All the included studies assessed the effects of ezetimibe plus other lipid‐modifying drugs compared with other lipid‐modifying drugs alone or plus placebo. Among the included studies, 25 compared ezetimibe plus statin versus statin alone or plus placebo, and the other compared ezetimibe plus fenofibrate versus fenofibrate alone. Our findings from this comparison were driven by the largest study (<a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a>), whose weights ranged from 41.5% to 98.4% in the different meta‐analyses performed in this review. </p> <p>We found that the addition of ezetimibe to statin therapy probably reduces the risk of major adverse cardiovascular events (MACE) compared with statins alone. Studies reporting all‐cause mortality used ezetimibe with statin or fenofibrate and found they have little or no effect on this outcome. Adding ezetimibe to statins probably reduces the risk of non‐fatal myocardial infarction (MI) and non‐fatal stroke. Studies reporting cardiovascular mortality added ezetimibe to statin or fenofibrate, probably having little or no effect on this outcome. The need for coronary revascularisation might be reduced by adding ezetimibe to statin; however, no difference in coronary revascularisation rate was observed when a sensitivity analysis was limited to studies with a low risk of bias. </p> <p>In terms of safety, adding ezetimibe to statins may have little or no difference in the risk of hepatopathy. It is uncertain whether ezetimibe increases or decreases the risk of myopathy and rhabdomyolysis, given the wide confidence intervals and low event rate. Little or no difference in the risk of cancer, gallbladder‐related disease and discontinuation due to adverse events (AEs) were observed between treatment groups. However, the quality of the evidence for hepatopathy and myopathy was low and very low, respectively, due to imprecision and risk of bias. The analysis of serum lipids revealed that the addition of ezetimibe to statin or fenofibrate might further reduce: low‐density lipoprotein cholesterol (LDL‐C), total cholesterol (TC) and triglyceride (TG) levels and likely increase high‐density lipoprotein cholesterol (HDL‐C) levels; however, most analyses included substantial heterogeneity. </p> <p>None of the included studies reported on health‐related quality of life.</p> </section> <section id="CD012502-sec-0115"> <h3 class="title" id="CD012502-sec-0115">Overall completeness and applicability of evidence</h3> <p>This review provides a comprehensive appraisal of the evidence, but the applicability of the results has some limitations. First, the data in this review were obtained from studies of ezetimibe combined with statins or fenofibrate. The effects of ezetimibe monotherapy in preventing cardiovascular disease (CVD) and all‐cause mortality remain uncertain. </p> <p>Second, most participants in the included studies were diagnosed with atherosclerotic cardiovascular disease (ASCVD), predominantly with acute coronary syndrome (ACS) (more than 90%). Although a subgroup analysis showed that no difference in primary outcomes between individuals with and individuals without established ASCVD, the confidence interval was very wide and comparatively fewer individuals were included in the subgroup without ASCVD. Therefore, caution should be taken when extrapolating the results of this review to individuals without ASCVD, and the evidence regarding the use of ezetimibe for primary prevention remains uncertain. </p> <p>Third, it should be noted that in patients with ACS, the efficacy of lipid‐lowering drugs on CVD outcomes might be lower and confounded by underlying shifts in lipid levels due to the resolution of acute‐phase changes at least in the initial three to six months. A persistent finding of statin meta‐analyses (<a href="./references#CD012502-bbs2-0103" title="Cholesterol Treatment Trialists Collaboration, MihaylovaB , EmbersonJ , BlackwellL , KeechA , SimesJ , BarnesEH , et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta‐analysis of individual data from 27 randomised trials. Lancet2012;380(9841):581‐90. ">CTT 2012</a>) is that secondary prevention populations tend to show a slower time from drug administration to benefit (curve separation) than primary prevention populations, indicating that it takes three years for the full effects to be revealed. In this review, only three included studies were followed up for more than three years, and the remaining studies included a follow‐up duration of only one or two years. The follow‐up duration might be insufficient for the observation of the full effects of the treatment. The IMPROVE‐IT results showed that the benefit with ezetimibe began to emerge after one year of treatment, and continued over the ensuing years of the trial. This information suggests that its benefits are not associated with events immediately surrounding the acute ACS event, but rather its benefits are associated with reducing the atherosclerotic burden and the risk of events over the chronic phase of ischaemic heart disease. Thus the results have relevance when considering treatment for chronic coronary heart disease. </p> <p>Finally, our results for cardiovascular outcomes originated from the studies of ezetimibe in combination with statins; thus the cardiovascular benefit might not be applied to ezetimibe combined with fenofibrate due to a lack of evidence. </p> </section> <section id="CD012502-sec-0116"> <h3 class="title" id="CD012502-sec-0116">Quality of the evidence</h3> <p>We used GRADE to assess the quality of the evidence for the outcomes of MACE, all‐cause mortality, MI, stroke, cardiovascular mortality, hepatopathy and myopathy. See <a href="./full#CD012502-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>The quality of the evidence for all‐cause mortality was judged to be high, and that for cardiovascular mortality was judged to be moderate due to imprecision (the 95% CI includes both plausible harm and benefit). We judged the quality of the evidence for MACE, MI and stroke as moderate, mainly due to potential bias (as discussed in detail below). For AEs (hepatopathy and myopathy), we rated the quality of evidence as low for hepatopathy and very low for myopathy when considering the risk of bias together with imprecision (95% CI includes plausible harm and benefit). </p> <p>Our evidence was mainly driven by one large study (IMPROVE‐IT) that had weighs of more than 88% in the different meta‐analyses for clinical outcomes. This international, multi‐centre study was rated as low risk of bias. Although we included some studies that were judged to have unclear risk of bias or high risk of performance bias, they were unlikely to affect the results because the sample size of these studies was generally small. Moreover, the results were robust, as demonstrated in a sensitivity analysis that included only those studies with low risk of bias. </p> <p>However, we should carefully consider several caveats. First, after a median of six years, 42% of the IMPROVE‐IT study participants prematurely stopped taking their study medications, but all the participants, including those who discontinued from treatment, were monitored for suspected clinical endpoint events and AEs until the termination of the trial. At the end of the study, the vital status was obtained in 96% of all randomised participants, whereas approximately 11% of participants discontinued their follow‐up for the primary cardiovascular endpoint (MACE) prior to the close‐out period. Therefore, we did not downgrade mortality outcomes due to risk of bias, but we cannot ignore the potential impact of medication compliance or missing data on other outcomes. </p> <p>Second, it should be noted that the MACE outcome is a composite cardiovascular endpoint that contains five components in our review. Some studies that were included in the meta‐analysis have different definitions of MACE, which mainly did not include hospitalisation for unstable angina or coronary revascularisation (and did not provide data on these components). However, three studies, including the IMPROVE‐IT study, provided data for all components of MACE that were defined in this review and played a dominant role in the pooled results. </p> <p>Third, we also noted that coronary revascularisation contributed to a large proportion of MACE. This endpoint was investigator‐determined and based on many factors including LDL cholesterol levels, which could be biased and unblinded. From another perspective, the meta‐analysis for coronary revascularisation showed that ezetimibe had a marginal effect compared with the control treatment, whereas a sensitivity analysis that only included studies with a low risk of bias showed no difference between treatment groups. Therefore, we are not sure whether the pooled result for MACE was influenced by the differences in coronary revascularisation between the two groups. However, the significance of the pooled MACE result was likely influenced by the IMPROVE‐IT results, which were driven by differences in non‐fatal MI, non‐fatal stroke and urgent coronary revascularisations. </p> <p>Based on the above discussion, we downgraded the quality of the evidence for all the cardiovascular endpoints and AEs due to these potential biases. </p> <p>We judged imprecision by whether the 95% CI included the null, and whether it included important benefits and harms. Where the confidence interval of the overall effect included both no effect and potential benefit, we downgraded the evidence. Thus, we downgraded the evidence for cardiovascular mortality, hepatopathy and myopathy due to imprecision. </p> <p>We did not downgrade the quality of the evidence for any outcome due to inconsistency or indirectness. Although all the studies mainly included men (the IMPROVE‐IT study carried much of the weight in the meta‐analysis and did not have any interaction between gender and primary outcome), we did not downgrade the outcomes for indirectness. </p> <p>We judged publication bias according to whether there was any suggestion of publication or small‐study bias in the funnel plot. The funnel plots did not indicate any strong possibilities of publication bias (<a href="#CD012502-fig-0004">Figure 4</a> ‐ <a href="#CD012502-fig-0009">Figure 9</a>). </p> </section> <section id="CD012502-sec-0117"> <h3 class="title" id="CD012502-sec-0117">Potential biases in the review process</h3> <p>We performed a comprehensive search of major databases and clinical trial registry platforms. We also checked the reference lists of all primary studies and review articles for additional references. In addition, we used unpublished data of IMPROVE‐IT study from licensing applications that were submitted to the Food and Drug Administration (FDA). However, we might have missed clinical trials that have not been reported or are unregistered. </p> <p>When information on relevant outcomes was not reported, we attempted to contact the authors of the study, but only a limited number of responses was received. </p> <p>We only included studies with the follow‐up period of at least 12 months because long‐term trials might yield sufficient and reliable results of long‐term effects on mortality and cardiovascular morbidity. However, we excluded most studies due to their short‐term interventions, which limited the number of studies eligible for inclusion. </p> </section> <section id="CD012502-sec-0118"> <h3 class="title" id="CD012502-sec-0118">Agreements and disagreements with other studies or reviews</h3> <p>We identified five published reviews relevant to our review. Two reviews (<a href="./references#CD012502-bbs2-0099" title="BattaggiaA , DonzelliA , FontM , MolteniD , GalvanoA . Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta‐analysis of randomized controlled trials. PLoS One [Electronic Resource]2015;10(4):e0124587. ">Battaggia 2015</a>; <a href="./references#CD012502-bbs2-0133" title="SavareseG , DeFerrariGM , RosanoGM , Perrone‐FilardiP . Safety and efficacy of ezetimibe: A meta‐analysis. International Journal of Cardiology2015;201:247‐52. ">Savarese 2015</a>) both compared ezetimibe plus other lipid‐modifying drugs versus placebo or the same other lipid‐modifying drugs alone. One review (<a href="./references#CD012502-bbs2-0140" title="ThomopoulosC , SkalisG , MichalopoulouH , TsioufisC , MakrisT . Effect of low‐density lipoprotein cholesterol lowering by ezetimibe/simvastatin on outcome incidence: overview, meta‐analyses, and meta‐regression analyses of randomized trials. Clinical Cardiology2015;38(12):763‐9. ">Thomopoulos 2015</a>) compared ezetimibe/simvastatin with placebo or simvastatin alone. These three reviews all included the comparison of ezetimibe plus statins versus placebo alone, but we did not include this comparison because it only assessed the effect of the combination rather the ezetimibe. Thus, extrapolating the efficacy of ezetimibe from this comparison is questionable. </p> <p>Two other reviews (<a href="./references#CD012502-bbs2-0107" title="FeiY , GuyattGH , AlexanderPE , ElDibR , SiemieniukRAC , VandvikPO , et al. Addition of ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient‐important outcomes. Journal of Evaluation in Clinical Practice2018;24(1):222‐31. ">Fei 2018</a>; <a href="./references#CD012502-bbs2-0123" title="NusßaumerB , GlechnerA , Kaminski‐HartenthalerA , MahlknechtP , GartlehnerG . Ezetimibe‐statin combination therapy. Deutsches Arzteblatt International2016;113(26):445‐53. ">Nusßaumer 2016</a>) compared ezetimibe‐statin combination therapy with statin monotherapy. However, our review assessed the a combination therapy of ezetimibe with other lipid‐lowering drugs (not limited to statins), but we only identified studies that investigated ezetimibe in combination with statins or fenofibrate. </p> <p>All these reviews included studies with a follow‐up period of more than six months, whereas our review included studies with a follow‐up period of at least 12 months. We considered studies with long follow‐up periods may provide sufficient and reliable intervention effects on mortality and cardiovascular morbidity. Although longer follow‐up periods are needed, most of the studies included in the above‐mentioned reviews were included in our review. Furthermore, our review included more recent clinical trials. </p> <p>The results of Battagia's review suggested that ezetimibe does not offer benefit for all all‐cause mortality, cardiovascular mortality, MI and stroke. However, this review was published earlier and did not include the IMPROVE‐IT study. The other four reviews and our review included the IMPROVE‐IT study, and our results were largely consistent with these reviews, showing that ezetimibe moderately reduced the risk of MI and stroke. </p> <p>To date, the IMPROVE trial is the largest clinical trial of ezetimibe, and thus, this study plays a leading role in our results. Although our review included more recent studies than the previous reviews, these additional studies were small and did not significantly change the overall effect estimates. </p> <p>Overall, our review was more comprehensive than previous reviews because we included more studies, assessed more outcomes, used unpublished data that were submitted to regulatory bodies (FDA), and performed subgroup analyses and sensitivity analyses. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012502-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012502-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012502-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012502-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.1 MACE (subgroup analysis: duration of follow‐up)." data-id="CD012502-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.1 MACE (subgroup analysis: duration of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.34 Discontinuation due to adverse event." data-id="CD012502-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.34 Discontinuation due to adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.37 LDL‐C (end of follow up)." data-id="CD012502-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.37 LDL‐C (end of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.40 TC (end of follow up)." data-id="CD012502-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.40 TC (end of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.43 HDL‐C (end of follow up)." data-id="CD012502-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.43 HDL‐C (end of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.46 TG (end of follow up)." data-id="CD012502-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, outcome: 1.46 TG (end of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 1 MACE (subgroup analysis: duration of follow up)." data-id="CD012502-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 1 MACE (subgroup analysis: duration of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 2 MACE (subgroup analysis: participates with/without ASCVD)." data-id="CD012502-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 2 MACE (subgroup analysis: participates with/without ASCVD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 3 MACE (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 3 MACE (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 4 MACE (sensitivity analysis: random‐effects models)." data-id="CD012502-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 4 MACE (sensitivity analysis: random‐effects models). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 5 MACE (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 5 MACE (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 6 All‐cause mortality (subgroup analysis: duration of follow up)." data-id="CD012502-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 6 All‐cause mortality (subgroup analysis: duration of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 7 All‐cause mortality (subgroup analysis: participates with/without ASCVD)." data-id="CD012502-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 7 All‐cause mortality (subgroup analysis: participates with/without ASCVD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 8 All‐cause mortality (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 8 All‐cause mortality (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 9 All‐cause mortality (sensitivity analysis: random‐effects models)." data-id="CD012502-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 9 All‐cause mortality (sensitivity analysis: random‐effects models). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 10 All‐cause mortality (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 10 All‐cause mortality (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 11 Myocardial infarction (non‐fatal)." data-id="CD012502-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 11 Myocardial infarction (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 12 Myocardial infarction (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 12 Myocardial infarction (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 13 Myocardial infarction (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 13 Myocardial infarction (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 14 Ischaemic stroke (non‐fatal)." data-id="CD012502-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 14 Ischaemic stroke (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 15 Ischaemic stroke (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 15 Ischaemic stroke (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 16 Ischaemic stroke (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 16 Ischaemic stroke (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 17 Cardiovascular mortality." data-id="CD012502-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 17 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 18 Cardiovascular mortality (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 18 Cardiovascular mortality (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 19 Cardiovascular mortality (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 19 Cardiovascular mortality (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 20 Coronary revascularization." data-id="CD012502-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 20 Coronary revascularization. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 21 Coronary revascularization (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 21 Coronary revascularization (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 22 Coronary revascularization (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 22 Coronary revascularization (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 23 Adverse events ‐ hepatopathy." data-id="CD012502-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 23 Adverse events ‐ hepatopathy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 24 Adverse events ‐ hepatopathy (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 24 Adverse events ‐ hepatopathy (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 25 Adverse events ‐ myopathy." data-id="CD012502-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 25 Adverse events ‐ myopathy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 26 Adverse events ‐ myopathy (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 26 Adverse events ‐ myopathy (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 27 Adverse events ‐ rhabdomyolysis." data-id="CD012502-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 27 Adverse events ‐ rhabdomyolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 28 Adverse events ‐ rhabdomyolysis (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 28 Adverse events ‐ rhabdomyolysis (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 29 Adverse events ‐ cancer." data-id="CD012502-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 29 Adverse events ‐ cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 30 Adverse events ‐ cancer (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 30 Adverse events ‐ cancer (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 31 Adverse events ‐ cancer (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 31 Adverse events ‐ cancer (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 32 Adverse events ‐ gallbladder‐related AE." data-id="CD012502-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 32 Adverse events ‐ gallbladder‐related AE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 33 Adverse events ‐ gallbladder‐related AE (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 33 Adverse events ‐ gallbladder‐related AE (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-34.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 34 Discontinuation due to adverse event." data-id="CD012502-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 34 Discontinuation due to adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 35 Discontinuation due to adverse event (sensitivity analysis: only including low risk of bias studies)." data-id="CD012502-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 35 Discontinuation due to adverse event (sensitivity analysis: only including low risk of bias studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 36 Discontinuation due to adverse event (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 36 Discontinuation due to adverse event (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-37.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 37 LDL‐C (end of follow up)." data-id="CD012502-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 37 LDL‐C (end of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 38 LDL‐C (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 38 LDL‐C (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 39 LDL‐C (end of follow up) (sensitivity analysis: excluding studies with serious missing data)." data-id="CD012502-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 39 LDL‐C (end of follow up) (sensitivity analysis: excluding studies with serious missing data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-40.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 40 TC (end of follow up)." data-id="CD012502-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 40 TC (end of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 41 TC (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 41 TC (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 42 TC (end of follow up) (sensitivity analysis: excluding studies with serious missing data)." data-id="CD012502-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 42 TC (end of follow up) (sensitivity analysis: excluding studies with serious missing data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-43.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 43 HDL‐C (end of follow up)." data-id="CD012502-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 43 HDL‐C (end of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 44 HDL‐C (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 44 HDL‐C (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 45 HDL‐C (end of follow up) (sensitivity analysis: excluding studies with serious missing data)." data-id="CD012502-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 45 HDL‐C (end of follow up) (sensitivity analysis: excluding studies with serious missing data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-46.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 46 TG (end of follow up)." data-id="CD012502-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 46 TG (end of follow up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 47 TG (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone)." data-id="CD012502-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 47 TG (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012502-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/urn:x-wiley:14651858:media:CD012502:CD012502-CMP-001-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_t/tCD012502-CMP-001-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 48 TG (end of follow up) (sensitivity analysis: excluding studies with serious missing data)." data-id="CD012502-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 48 TG (end of follow up) (sensitivity analysis: excluding studies with serious missing data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/media/CDSR/CD012502/image_n/nCD012502-CMP-001-48.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012502-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ezetimibe plus other lipid‐modifying drugs compared to other lipid‐modifying drugs alone or plus placebo for the prevention of cardiovascular disease and all‐cause mortality events</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cardiovascular disease or at high risk of cardiovascular disease<br/> <b>Setting:</b> inpatients or outpatient<br/> <b>Intervention:</b> ezetimibe plus other lipid‐modifying drugs (statin or fenofibrate)<br/> <b>Comparison:</b> other lipid‐modifying drugs (statin or fenofibrate) alone or plus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other lipid‐modifying drugs alone or plus placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Ezetimibe plus other lipid‐modifying drugs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major adverse cardiovascular events (MACE)<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.90 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,727<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 88.8% of the weight.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1,000<br/> (256 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.91 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,222<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The IMPROVE‐IT study carried 94.6% of the weight.</p> <p>Two additional studies reported that no deaths occurred, and one study reported the total deaths but did not provide data by treatment arm. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1,000<br/> (112 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction (non‐fatal)<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.81 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,145<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 97.8% of the weight, and also provided data on any MI (HR 0.87, 95% CI 0.80 to 0.95) and fatal MI (HR 0.84, 95% CI 0.55 to 0.1.27). </p> <p>Two additional studies reported that no MI events occurred.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/> (85 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke (non‐fatal)<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/> (0.71 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,205<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 89.4% of the weight, and also provided data on any stroke (HR 0.86, 95% CI 0.73 to 1.00), ischaemic stroke (HR 0.79, 95% CI 0.67 to 0.94), haemorrhagic stroke (HR 1.38, 95% CI 0.93 to 2.04) and fatal stroke (HR 1.22, 95% CI 0.81 to 1.82). </p> <p>One additional study reported that no stroke events occurred.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1,000<br/> (23 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/> (0.89 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19,457<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The IMPROVE‐IT study carried 98.4% of the weight.</p> <p>Four additional studies reported that no cardiovascular death occurred and one study reported total cardiac deaths but did not provide data by treatment arm. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1,000<br/> (50 to 63) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ hepatopathy<br/> follow‐up: range 1 to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/> (0.96 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20,687<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 89.6% of the weight.</p> <p>Ten additional studies reported no occurrence in the levels of ALT and/or AST being more than or equal 3 x ULN. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/> (22 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ myopathy<br/> follow‐up: range 1 years to 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.31<br/> (0.72 to 2.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20,581<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data were obtained from studies comparing ezetimibe plus statin versus statin alone. </p> <p>The IMPROVE‐IT study carried 52.5% of the weight.</p> <p>Thirteen additional studies reported that none of the participants in either group developed a CK level more than or equal 10 x ULN. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/> (1 to 4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to risk of bias. </p> <p><sup>2</sup> Downgraded by one level due to imprecision (the 95% CI exclude serious harm, but included the null). </p> <p><sup>3</sup> Downgraded by one level due to imprecision (the 95% CI of the overall effect included both no effect and important harm). </p> <p><sup>4</sup> Downgraded by two levels due to imprecision (few events and wide CI). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012502-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of included studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Location</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Centres</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised</b> </p> <p>(intervention/control)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> (years) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical setting</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> <p>(multinational)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201/45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>primary hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/d +ezetimibe10 mg/d</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/day + placebo</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118/59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hyperlipidaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fenofibrate 160 mg˜200 mg/day + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fenofibrate 160 mg˜200 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the Netherlands (multinational)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357/363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>familial hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 80 mg/day + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 80 mg/day + placebo</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute coronary syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pitavastatin 2 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pitavastatin 2 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>869/865</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.86 (median)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute coronary syndrome and dyslipidaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pitavastatin¹ + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pitavastatin²</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> <p> (multinational)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9067/9077</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (median)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute coronary syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + ezetimibe10mg/d</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + placebo</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>stable angina pectoris</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fluvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fluvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 in total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>asymptomatic, 'statin naive' patients with maximum carotid stenosis &gt;50%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greece</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126/136</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>undergoing vascular surgery</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ezetimibe 10 mg/day + rosuvastatin 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rosuvastatin 10 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114/116</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute coronary syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74/74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary heart disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danish</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43/44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ST‐segment elevation myocardial infarction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 80 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 80 mg/day + placebo</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100/100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary heart disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin (atorvastatin 10 mg/day or rosuvastatin 2.5 mg/day) + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin(atorvastatin 20 mg/day or rosuvastatin 5 mg/day )</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>acute myocardial infarction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rosuvastatin 10 mg/day + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rosuvastatin 10 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin (atorvastatin 10 mg/day or pitavastatin 1 mg/day ) + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin(atorvastatin 20 mg/day or pitavastatin 2 mg/day )</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122/124</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypercholesterolemia and Coronary Artery Disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin³ + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin³</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 in total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (mean)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hypercholesterolaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pravastatin 5 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pravastatin 10 mg</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>multi‐centres</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148/148</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>chronic kidney disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin⁴ + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>statin⁴</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>high risk patiens of coronary artery disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/51</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary atherosclerotic heart disease and hyperlipidaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ezetimibe 10 mg/day + rosuvastatin 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rosuvastatin 10 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51/49</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary heart disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 20 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>peripheral arterial disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + ezetimibe 10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>chronic kidney disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>simvastatin 40 mg/day</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single‐centre</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>coronary heart disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/day + ezetimibe10 mg/day</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>atorvastatin 10 mg/day</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>¹Starting dose for pitavastatin was 2 mg, adjusted the dosage to target LDL‐C of 70 mg/dL. </p> <p>²Starting dose for pitavastatin was 2 mg, adjusted the dosage to target LDL‐C of between 90 mg/dL and 100 mg/dL. </p> <p>³Atorvastatin was increased by titration within the usual dose range with a treatment goal of LDL‐C &lt; 70 mg/dL. </p> <p>⁴The choice of statins was at the discretion of the physician.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012502-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (mean ± SD)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Male%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI (mean ± SD)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes mellitus%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypertension%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>History of CHD%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>History of MI%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PAD%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stain</b> </p> <p><b>pretreatment%</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.7 ± 14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.6 ± 12.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4 ± 4.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.03</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.9 ± 9.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 ± 4.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 ± 11.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.1 ± 11.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3 ± 3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.6 ± 9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.3 ± 5.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.3 ± 11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.8 ± 5.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0009" title="KodaliS , DoyleM , GrantS , NeffD , WilliamsRB , YamrozikJ , et al. Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis. Journal of Cardiovascular Magnetic Resonance2012;14(SUPPL 1):O43. KodaliS , DoyleM , GrantSB , NeffDR , WilliamsRB , YamrozikJA , et al. A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance. Conference2011;13(SUPPL 1):P178. ">Kodali 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 ± 12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (washout)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.1 ± 2.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.5 ± 3.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66. ± 76.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.6 ± 4.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2 ± 12.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0 ± 5.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.3 ± 10.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.3/27.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.8 ± 9.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.2 ± 3.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.0 ± 2.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.2 ± 10.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.5 ± 10.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.9 ± 3.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0019" title="SawayamaY . Low‐dose pravastatin plus ezetimibe verus standard‐dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia. Atherosclerosis Supplements2011;12 (1):180. ">Sawayama 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0020" title="SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306‐15. UMIN000002935 . A community‐based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002935 (date of registration 1 January 2010). ">Suzuki 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 ± 12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.5 ± 1.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.5 ± 8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 ± 5.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.0 ± 11.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 ± 9.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.6 ± 9.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.9 ± 6.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0025" title="CarruC , LorigaG , FarreG , ZinelluA , SotgiaS , ScanuB , et al. An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin/ezetimibe combined therapy. Atherosclerosis Supplements2010;11(2):192‐3. NCT00861731 . Ezetimibe/simvastatin combination in proteinuric nephropathy (VICTORY). clinicaltrials.gov/ct2/show/NCT00861731 (first posted 13 March 2009). PisanuE , SannaM , ScanuB , SattaAE , DeianaL , ZinelluA . Lipid lowering therapy decreases LDL‐S‐homocysteinilation levels in chronic kidney desease patients. FEBS Journal2012;279(SUPPL 1):104. SannaM , PisanuE , CambeddaD , EnaS , LorigaG , CarruC . Effect of combined simvastatin/ezetimibe administration on taurine levels and oxidative status in patients CDK. FEBS Journal2012;279(SUPPL 1):218. ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid‐lowering therapy. Amino Acids2012;43(4):1499‐507. ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism and Cardiovascular Diseases2015;25(2):153‐9. ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383‐8. ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S‐homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117‐23. ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases2017; Vol. 27, issue 9:822‐9. ">Zinellu 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 ± 10.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.8 ± 6.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>BMI: body mass index; CHD: coronary heart disease; MI: myocardial infarction; NR: not reported; PAD: peripheral arterial disease; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012502-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of changes in lipid parameters</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> <p>　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Intervetion or control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>LDL‐C (mean ± SD, mg/dL</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>TC (mean ± SD, mg/dL)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>HDL‐C (mean ± SD, mg/dL</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>TG (mean ± SD, mg/dL)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>end</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%change from baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>end</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%change from baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>end</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%change from baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>baseline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>end</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%change from baseline</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0001" title="BallantyneCM , LipkaLJ , SagerPT , StronyJ , AlizadehJ , SureshR , et al. Long‐term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice2004;58(7):653‐8. ">Ballantyne 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐48.4 ± 18.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐35.4 ± 14.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 ± 13.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):–29.6 (–40.3 to ‐15.1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐38.6 ± 12.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐27.5 ±10.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 ± 3.13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):–16.9 (–30.7 to 5.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0002" title="OikawaS , YamashitaS , NakayaN , SasakiJ , Kono S for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis &amp; Thrombosis2017;24(1):77‐94. OikawaS , YamashitaS , NakayaN , SasakiJ , KonoS , Investigators G Efectl Study. Efficacy and safety of long‐term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Atherosclerosis2016;252:E230. UMIN000001224 . Effect of fenofibrate and ezetimibe combination treatment on lipid. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000001224. ">EFECTL 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 ± 27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 ± 26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−28.9 ± 15.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263 ± 30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197 ± 28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−24.2 ± 10.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 ± 10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 ± 13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3 ± 17.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266 ± 77</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 ± 74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−44.9 ± 27.3</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 ± 31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 ± 29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−17.3 ± 14.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 ± 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 ± 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−14.8 ± 11.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ± 10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 ± 14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2 ± 23.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266 ± 106</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 ± 93</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−31.8 ± 45.6</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0003" title="KasteleinJ , SagerP , DeGrootE , VeltriE . The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Atherosclerosis Supplements2003;4(2):341. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine2008;358(14):1431‐43. KasteleinJJ , AkdimF , StroesES , ZwindermanAH , BotsML , StalenhoefAF , et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]. New England Journal of Medicine2008;358(18):1977. KasteleinJJ , SagerPT , deGrootE , VeltriE . Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. American Heart Journal2005;149(2):234‐9. KasteleinJJ , StronyJ , SagerPT , deGrootE , VeltriEP . The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression. Stroke2004;35(6):E258. NCT00552097 . Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE). https://clinicaltrials.gov/ct2/show/NCT00552097. ">ENHANCE 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319.0 ± 65.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141.3 ± 52.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐55.6 ± 17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400.0 ± 67.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217.3 ± 56.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐45.3 ±15.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.7 ±11.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.9 ± 12.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 ±18.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):157(113 to 217)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):108 (82 to 148)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):‐29.8(‐43.5 to 11.5)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317.8 ± 66.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192.7 ± 60.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐39.1 ± 17.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400.0 ± 68.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270.6 ± 61.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐31.9 ±15.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.4 ±13.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.7 ± 14.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8 ±17.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):160 (114 to 227)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):120(89 to 164)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):‐23.2(‐37.0 to 1.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0004" title="HibiK , KimuraK , SonodaS , OtsujiY , MuroharaT , IshiiH , et al. Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome. Circulation2015;132(SUPPL 3):14134. HibiK , SonodaS , KawasakiM , OtsujiY , MuroharaT , IshiiH , et al. Effects of ezetimibe‐statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circulation Journal2018;82(3):757‐66. ">Hibi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123±32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64±18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 ± 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 ± 20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ±14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 ± 12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 ± 64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 ± 53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126±33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87±21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 ± 37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 ± 29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ±11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 ±15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 ± 52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129 ± 77</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0005" title="HagiwaraN , Kawada‐WatanabeE , KoyanagiR , ArashiH , YamaguchiJ , NakaoK , et al. Low‐density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ‐PROPER study, a prospective, open‐label, randomized trial. European Heart Journal2017;38(29):2264‐79. KanbayashiK , YamaguchiJ , FujiiS , Kawada‐WatanabeE , ArashiH , SekiguchiH , et al. The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER. European Heart Journal2017; Vol. 38, issue Supplement 1:237. Kawada‐WatanabeE , OgawaH , KoyanagiR , ArashiH , YamaguchiJ , MatsuiK , et al. Rationale, design features, and baseline characteristics: the Heart Institute of Japan‐PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ‐PROPER). Journal of Cardiology2017;69(3):536‐41. SekiguchiH , Kawada‐WatanabeE , ArashiH , YamaguchiJ , OgawaH , HagiwaraN . Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER. Circulation2017;136(Supplement 1):A18891. UMIN000002742 . Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002742. WatanabeE , OgawaR , YamaguchiJ , SekiguchiH , OgisoM , ArashiH , et al. Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy. Journal of the American College of Cardiology2018;71(Supplement 1):A53. YamaguchiJ , Kawada‐WatanabeE , KoyanagiR , ArashiH , SekiguchiH , NakaoK , et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub‐analysis of HIJ‐PROPER. Atherosclerosis2018;274:139‐45. ">HIJ‐PROPER 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134.8 ± 29.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.3 ± 24.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135.6 ± 30.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.5 ± 21.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I<a href="./references#CD012502-bbs2-0006" title="AmbrosyAP , CerbinLP , ClareR , LokhnyginaY , TershakovecA , RoeMt , et al. The natural history of patients post‐acute coronary syndrome based on heart failure status‐an analysis of the improve‐it trial. Circulation2017; Vol. 136, issue Supplement 1:A17275. BachRG , CannonC , GiuglianoR , WhiteJ , LokhnyginaY , TershakovecA , et al. Increasing age and the benefit from higher‐intensity lipid lowering with ezetimibe/simvastatin vs. simvastatin alone: Results from the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A16708. BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE‐IT study population. American Heart Journal2014;168(2):205‐12.e1. BlazingMA , GiuglianoRP , DeLemosJ , CannonCP , MuslinerT , TershakovecAM , et al. On‐Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). Circulation2014;130(23):2112. BlazingMA , GiuglianoRP , WiviottSD , WhiteJA , DelemosJA , McGuireDK , et al. Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE‐IT study. European Heart Journal2015;36(SUPPL 1):1151. BlazingMA , GiuglianoRP , deLemosJA , CannonCP , TonkinA , BallantyneCM , et al. On‐treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT). American Heart Journal2016;182:89‐96. BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation2015;132(13):1224‐33. BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911‐21. BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; Vol. 136, issue 25:2440‐50. Bohula MayEA , GiuglianoRP , CannonCP , MurphySA , ZhouJ , BlazingMA , et al. Achievement of dual LDL‐C (&lt;70 mg/dL) and hs‐CRP (&lt;2 mg/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE‐IT. European Heart Journal2015;36(SUPPL 1):1060. Bohula MayEA , WhiteJA , BlazingM , GiuglianoR , MuslinerT , TershakovecA , et al. Risk stratification for cardiovascular events in the improve‐it trial. Journal of the American College of Cardiology2015;65(10 SUPPL 1):A3. CaliffRM , LokhnyginaY , CannonCP , StepanavageME , McCabeCH , MuslinerTA , et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) design. American Heart Journal2010;159(5):705‐9. CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387‐97. CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. CannonCP , Investigators Improve It. IMPROVE‐IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation2014;130(23):2109. FanaroffAC , NavarAM , ClareR , LokhnyginaY , RoeM , GiuglianoR , et al. Association of type of presentation, STEMI vs NSTEMI/UA, with the relative long‐term incidence of cardiovascular and non‐cardiovascular mortality. Circulation2016;134(Supplement 1):A18895. FanaroffAC , RoeMT , ClareRM , LokhnyginaY , NavarAM , GiuglianoRP , et al. Competing risks of cardiovascular versus noncardiovascular death during long‐term follow‐up after acute coronary syndromes. Journal of the American Heart Association2017;6(9):e005840. GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137:1571‐82. GiuglianoRP , CannonCP , BlazingMA , WhiteJ , MurphyS , TershakovecA , et al. Baseline LDL‐C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. Journal of the American College of Cardiology2015;65(10):A4. GiuglianoRP , WiviottSD , BlazingMA , DeFerrariGM , ParkJeong‐Gun , MurphySA , et al. Long‐term safety and efficacy of achieving very low levels of low‐density lipoprotein cholesterol : A prespecified analysis of the IMPROVE‐IT Trial. JAMA Crdiology2017;2(5):547‐55. GiuglianoRP , WiviottSD , FuchsCS , WagnerAJ , GoesslingW , WhiteJA , et al. Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial. European Heart Journal2015;36:181. KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017; Vol. 6, issue 11:e006901. KatoET , GiuglianoRP , BlazingMA , MayEB , GuneriS , WhiteJA , et al. Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A17862. MagnusonEA , ChinnakondepalliK , VilainK , MarkDB , DaviesG , GiuglianoRP , et al. Impact of ezetimibe on hospitalization‐related costs among patients with a recent acute coronary syndrome: Results from the improve‐it trial. Circulation2015;132(SUPPL 3):A13035. MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post‐acute coronary syndrome: the IMPROVE‐IT Trial. Journal of the American College of Cardiology2016;67(4):353‐61. NCT00202878 . IMPROVE‐IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin. https://clinicaltrials.gov/ct2/show/NCT00202878. PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular‐related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE‐IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality and Outcomes2017;10(5):e003201. QamarA , GiuglianoRP , BlazingMA , ParkJG , MurphySA , CannonCP , et al. Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE‐IT trial. Circulation2017; Vol. 136, issue Supplement 1. SilvermanMG , CannonC , BlazingM , MachF , ZhouJ , TershakovecA , et al. Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE‐IT). Journal of the American College of Cardiology2016;67(13 SUPPL 1):484. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonC , BlazingMA . Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate. European Heart Journal2016;37(Supplement 1):1205. StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034‐43. U.S.Food , DrugAdministration . 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm (accessed 9 October 2017). WiviottSD , GiuglianoRP , BlazingMA , CannonCP , ZhouJ , MurphySA , et al. Reduction in non‐hemorrhagic stroke with ezetimibe/simvastatin compared with simvastatin alone in the IMPROVE‐IT trial. Circulation2015;132(SUPPL 3):A19694. ">IMPROVE‐IT 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:93.8; median(25th, 75th):95.0(79.0, 110.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:53.2; median(25th, 75th):50.0 (39.0, 62.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:162.7; median(25th, 75th):162.4 (144.0, 181.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:125.8; median(25th, 75th):121.0 (107.0, 139.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:42.1; median(25th, 75th):40.0 (33.0, 49.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:48.7; median(25th, 75th):47.0 (40.0, 56.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:137.6; median (25th, 75th):120.0 (85.0, 172.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:120.4; median (25th, 75th):104.0 (77.0, 143.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:93.8; median(25th, 75th):95.0(79.0, 110.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:69.9; median(25th, 75th): 67.0 (55.0, 81.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:162.6; median(25th, 75th):162.4 (144.0, 181.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:145.1; median(25th, 75th):142.0 (126.0, 160.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:42.2; median(25th, 75th):40.0 (33.0, 49.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:48.1; median(25th, 75th):46.0 (39.0, 55.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:137.5; median (25th, 75th):121.0 (85.0, 172.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean:137.1; median (25th, 75th):116.0 (84.0, 165.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0007" title="KatohA , HattoriY , YoshikwaN , NiiyamaH , HaradaH , KaiH , et al. The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins. European Heart Journal2017; Vol. 38, issue Supplement 1:188. ">Katoh 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 ± 27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 ± 18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 ± 27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 ± 16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0008" title="KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of Atherosclerosis &amp; Thrombosis2013;20(3):245‐56. KinouchiK , IchiharaA , BokudaK , MorimotoS , ItohH . Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin. Journal of Hypertension2012;30(SUPPL 1):e214. ">Kinouchi 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 ± 21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 ± 29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐30.0 ± 15.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249 ± 30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 ± 37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐21.6±11.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54±12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 ±11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 ± 14.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):144(78 to 218)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):121(88 to 180)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median(IQR):‐16.0(‐31.9 to 10.5)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 ± 20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 ± 23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐20.8 ± 13.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242 ± 26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207 ± 26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐14±8.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 ±16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 ±15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 ± 13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):149(103 to 213)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):152(86 to 215)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):2.7(‐29.9 to 43.1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0010" title="KouvelosG , MilionisH , ArnaoutoglouE , KostaraC , PapaN , KoulourasV , et al. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery2011;12(SUPPL 1):S61‐2. KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5‐12. KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128‐35. ">Kouvelos 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148.2 ± 58.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.9 ± 31.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243.3 ± 63.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154.1 ± 35.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.9 ±12.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.7 ±9.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 ± 54.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.2 ± 31.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239.3 ± 63.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167.6 ± 36.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.3 ±11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.7 ±10.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0011" title="LiuZ , HaoH , YinC , ChuY , LiJ , XuD . Therapeutic effects of atorvastatin and ezetimibe compared with double‐dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget2017;8(25):41582‐9. ">Liu 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.1 ± 23.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.4 ± 23.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.4 ± 11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.4 ±15.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132.9 ± 88.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124.0 ± 79.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.9 ± 30.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1 ± 27.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.3±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.4 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141.7 ± 132.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115.1 ± 79.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0012" title="LuoP , LiL , WangLX , ZhuHH , DuS , WuSL , et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics &amp; Molecular Research2014;13(2):2377‐84. ">Luo 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126.4 ± 14.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.3 ± 20.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222.4 ± 61.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191.4 ± 55.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.2 ±14.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.6 ± 8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201.9 ± 42.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157.7 ± 56.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130.0 ± 17.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106.3 ± 22.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227.4 ± 54.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199.5 ± 51.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6 ±17.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.8 ± 15.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208.1 ± 56.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157.7 ± 39.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0013" title="LuoP , WangL , ZhuH , DuS , WangG , DingS . Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease. Acta Cardiologica Sinica2016;32(5):578‐85. ">Luo 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138.0 ± 14.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.0 ± 22.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227.3 ± 56.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195.6 ± 57.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.2 ±15.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4 ±8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219.7 ± 39.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187.0 ± 42.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136.1 ± 17.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101.7 ± 21.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231.2 ± 56.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204.1 ± 56.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.0 ±17.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.6 ± 17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226.8 ± 56.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200.2 ± 56.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0014" title="HougaardM , HansenHS , JunkerA , ThayssenP , AntonsenL , MaeharaA , et al. Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial). Journal of the American College of Cardiology2014;64(11 Suppl 1):B112. HougaardM , HansenHS , ThayssenP , AntonsenL , JunkerA , VeienK , et al. Influence of ezetimibe in addition to high‐dose atorvastatin therapy on plaque composition in patients with ST‐segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine2017;18(2):110‐7. NCT01385631 . Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS). clinicaltrials.gov/ct2/show/NCT01385631 (first posted 30 June 2011). ">OCTIVUS 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143.1 ± 27.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.1 ± 30.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐62.0 ± 19.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204.9 ± 34.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112.1 ± 38.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐46.8±16.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6 ± 25.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158.5 ± 34.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3 ±19.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐52.4 ± 10.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220.4 ± 38.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135.3 ± 27.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐38.9±9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5 ±11.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1 ± 18.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0015" title="OkadaK , FukuiK , HimenoH , EndoT , ShimizuM , KobayashiS , et al. Long‐term effect of ezetimibe‐statin combination therapy on low‐density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis. Journal of the American College of Cardiology2011;57(14 SUPPL 1):E524. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe plus statin combination vs double‐dose statin therapy on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with statins; focus on proprotein convertase subtilisin/kexin type 9. Circulation2012;126(21 SUPPL 1):A10846. OkadaK , IwahashiN , EndoT , HimenoH , FukuiK , KobayashiS , et al. Long‐term effects of ezetimibe‐plus‐statin therapy on low‐density lipoprotein cholesterol levels as compared with double‐dose statin therapy in patients with coronary artery disease. Atherosclerosis2012;224(2):454‐6. OkadaK , KimuraK , IwahashiN , EndoT , HideoH , ShimizuM , et al. The mechanism of long‐term low‐density lipoprotein cholesterol lowering effect of ezetimibe‐plus‐statin combination therapy in coronary artery disease patients; compared with double‐dose statin therapy. Journal of the American College of Cardiology2012;59(13 SUPPL 1):E1541. OkadaK , KimuraK , IwahashiN , EndoT , HimenoH , FukuiK , et al. Long‐term effect of ezetimibe‐plus‐statin vs double‐dose statin on low‐density lipoprotein cholesterol lowering in coronary artery disease patients pre‐treated with a statin focus on cholesterol absorption and synthesis. Circulation2011;124(21 SUPPL 1):A12204. ">Okada 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119.9 ± 22.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.1 ± 20.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193.8 ± 26.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162.9 ± 28.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.4± 11.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.5 ±12.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):139.0(92.0 to 197.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):127.5(98.3 to 181.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.3 ± 23.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.8 ± 21.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189.8 ± 24.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.9 ± 25.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.3 ± 12.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.9 ± 13.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):131(76.0 to 167.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):124.5(87.3 to 155.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0017" title="RenY , ZhuH , FanZ , GaoY , TianN . Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine2017; Vol. 14, issue 5:4942‐50. ">Ren 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116.0 ± 37.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.0 ± 16.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175.9 ± 58.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.0 ± 38.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.2 ± 10.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.5 ± 21.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170.1 ± 101.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.7 ± 47.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113.3 ± 39.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.6 ± 19.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165.5 ± 49.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117.2 ± 24.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.0 ± 8.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.5 ± 16.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156.8 ± 92.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123.1 ± 95.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0018" title="InazawaT , SakamotoK , KohroT , IijimaR , KitazawaT , HiranoT , et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL‐C Goal), a randomized, doctor‐oriented, multicenter trial to compare the effects of higher‐dose statin versus ezetimibe‐plus‐statin on the serum LDL‐C concentration of Japanese type‐2 diabetes patients design and rationale. Lipids in Health and Disease2013;12:142. KawamuraM , WatanabeT , SakamotoK , AshidateK , KohroT , TanakaA , et al. RESEARCH: Superior effect of ezetimibe was sustained on LDL‐C level and the rate of achievement of target value in a 52‐week analysis. Diabetologia2015;58(SUPPL 1):S82. SakamotoK , KawamuraM , WatanabeT , AshidateK , KohroT , TanakaA , et al. Effect of ezetimibe add‐on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease2017;16(1):122. UMIN000002593 . Recognized effect of statin and ezetimibe therapy for achievement LDL‐C goal. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000002593 (date of registration 7 October 2009). ">RESEARCH 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 ± 21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.8 ± 19.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐28.3 ± 20.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211 ± 29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.3 ± 25.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐16.7±14.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.7 ± 15.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.7 ± 12.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR　</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 ± 95</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153.2 ± 73.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 ± 24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114.7 ± 21.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.19 ± 20.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 ± 27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198.5 ± 23.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.6±14.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.7 ± 9.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.3 ± 8.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 ± 88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160.2 ± 73.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0016" title="FujisueK , NagamatsuS , ShimomuraH , YamashitaT , NakaoK , NakamuraS , et al. Impact of statin‐ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease ‐ Sub‐analysis of PRECISE‐IVUS trial. International Journal of Cardiology2018;268:23‐6. FujisueK , NagamatsuS , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub‐analysis of precise‐IVUS trial. Journal of the American College of Cardiology2018;71(11 SUPPL 1):A1781. NCT01043380 . Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS). https://clinicaltrials.gov/ct2/show/NCT01043380. NagamatsuS , TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without chronic kidney disease‐subanalysis of precise‐IVUS trial. Circulation2016; Vol. 134, issue SUPPL 1:A14740. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Impact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. Journal of the American College of Cardiology2015;66(5):495‐507. TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , YamanagaK , et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE‐IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology2015;66(4):353‐8. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE‐IVUS trial. Atherosclerosis2016; Vol. 251:367‐72. TsujitaK , YamanagaK , KomuraN , SakamotoK , SugiyamaS , SumidaH , et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE‐IVUS trial. European Journal of Preventive Cardiology2016; Vol. 23, issue 14:1524‐8. TsujitaK , YamanagaK , KomuraN , ShimomuraH , IshiharaM , KaikitaK , et al. Dual lipid‐lowering with ezetimibe/statin as a promising anti‐atherosclerotic strategy. Journal of the American College of Cardiology2016;67(13):2132. TsujitaK , YamanagaK , SugiyamaS , ShimomuraH , YamashitaT , SakamotoK , et al. Impact of statin‐ezetimibe combination on coronary atheroma progression/regression in patients with and without prior statin therapy‐subanalysis of precise‐IVUS trial. Circulation2015;132(SUPPL 3):A13849. YamanagaK , TsujitaK , SugiyamaS , SumidaH , ShimomuraH , YamashitaT , et al. The impact of statin‐ezetimibe combination therapy in patients with decreased cholesterol absorption ability. Circulation2015; Vol. 132, issue SUPPL 3. ">PRECISE‐IVUS 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.8 ± 25.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.2 ± 16.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐40 ± 18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177.3 ± 32.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129.4 ± 22.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐25±17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.1 ± 9.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6 ± 11.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 ± 26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):114 median(IQR):(81 to 158)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):92 (76 to 120)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):–14 (–33 to 18)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108.3 ± 26.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3 ± 20.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐29 ± 24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172.7 ± 32.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138.7 ± 26.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐18±18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0 ±10.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.3 ± 11.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 ± 25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):116 (92 to 159)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):111 (87 to 139)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median (IQR):–9 (–33 to 25)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0021" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima‐media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49(7):838‐47. ">VYCTOR 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 ± 39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 ± 31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 ± 40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 ± 28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ± 11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ± 11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 ± 82</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 ± 90</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 ± 33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ± 37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215 ± 38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 ± 24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ± 9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ±10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198 ± 86</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 ± 79</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0022" title="WangX , ZhaoX , LiL , YaoH , JiangY , ZhangJ . Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart, Lung and Circulation2016;25(5):459‐65. ">Wang 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140.0 ± 45.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.0 ± 32.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218.4 ± 95.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124.1 ± 31.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.7 ± 8.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.7 ± 15.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.5 ± 59.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105.4 ± 28.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134.5 ± 48.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5 ± 30.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215.7 ± 99.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155.4 ± 35.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.7 ± 8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.3 ± 18.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174.5 ± 57.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155.9 ± 33.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0023" title="WangJ , AiXB , WangF , ZouYW , LiL , YiXL . Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International Angiology2017; Vol. 36, issue 5:467‐73. ">Wang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136.5 ± 33.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 ± 16.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203.4 ± 25.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117.9 ± 23.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170.1 ±16.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116.0 ± 17.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133.4 ±29.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.9 ± 24.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204.2 ± 26.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172.5 ± 24.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169.2 ± 18.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156.8 ± 48.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0024" title="NCT00587678 . Comprehensive magnetic resonance of peripheral arterial disease. https://clinicaltrials.gov/ct2/show/NCT00587678. WestAM , AndersonJD , EpsteinFH , MeyerCH , WangH , HagspielKD , et al. Low‐density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. Journal of the American College of Cardiology2011;58(10):1068‐76. WestAM , AndersonJD , MeyerCH , EpsteinFH , HagspielKD , BerrSS , et al. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010;12(SUPPL 1):192. WestAM , AndersonJD , MeyerCH , EpsteinFH , WangH , HagspielKD , et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis2011;218(1):156‐62. WestAM , PeschAJ , MehtaN , AndersonJD , EpsteinFH , MeyerCH , et al. Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy. Journal of Cardiovascular Magnetic Resonance2011;13(SUPPL1):P382. ">West 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 ± 9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 ± 42.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 ± 10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136 ± 50.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 ± 4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 ± 12.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 ± 21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 ± 84.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 ± 10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 ± 44.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 ± 11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 ± 48.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ± 4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 ± 16.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 ± 47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 ± 120.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012502-bbs2-0026" title="ZouYC , LuY , BaiJ , GaoY , LiY . Effect of ezetimibe combined with low‐dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease. Journal of the American Geriatrics Society2016;64:S328. ">Zou 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149.3 ± 24.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.5 ± 21.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210.0 ± 35.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139.6 ±16.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.5±13.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.7 ± 8.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287.0 ± 70.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171.0 ± 46.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148.1 ±0.84</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114.1 ± 21.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211.1 ± 36.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172.9 ± 26.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.9±10.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.6 ± 7.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281.7 ± 73.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215.2 ± 65.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="14"> <div class="table-footnote"> <p>Four studies did not provide lipids data; IQR: interquartile range; NR: not reported; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of changes in lipid parameters</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/full#CD012502-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012502-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 MACE (subgroup analysis: duration of follow up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 follow up &gt; 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 follow up ≤ 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MACE (subgroup analysis: participates with/without ASCVD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 with ASCVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 without ASCVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.56, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 MACE (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 MACE (sensitivity analysis: random‐effects models) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 MACE (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality (subgroup analysis: duration of follow up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 follow up &gt; 2 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.91, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 follow up ≤ 2 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.61, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause mortality (subgroup analysis: participates with/without ASCVD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 with ASCVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 without ASCVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.16, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause mortality (sensitivity analysis: random‐effects models) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 All‐cause mortality (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Myocardial infarction (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.81, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Myocardial infarction (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.81, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Myocardial infarction (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.81, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Ischaemic stroke (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.71, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Ischaemic stroke (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.67, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Ischaemic stroke (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.69, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Cardiovascular mortality (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Cardiovascular mortality (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Coronary revascularization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.89, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Coronary revascularization (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.89, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Coronary revascularization (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.89, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse events ‐ hepatopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.96, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse events ‐ hepatopathy (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse events ‐ myopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.72, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse events ‐ myopathy (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.73, 3.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse events ‐ rhabdomyolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.40, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse events ‐ rhabdomyolysis (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse events ‐ cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse events ‐ cancer (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adverse events ‐ cancer (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Adverse events ‐ gallbladder‐related AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.75, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Adverse events ‐ gallbladder‐related AE (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Discontinuation due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.75, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Discontinuation due to adverse event (sensitivity analysis: only including low risk of bias studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.78, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Discontinuation due to adverse event (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.76, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 LDL‐C (end of follow up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.79 [‐17.36, ‐16.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 LDL‐C (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.88 [‐17.45, ‐16.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 LDL‐C (end of follow up) (sensitivity analysis: excluding studies with serious missing data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.80 [‐17.38, ‐16.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 TC (end of follow up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.70 [‐20.48, ‐18.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 TC (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.77 [‐20.55, ‐18.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 TC (end of follow up) (sensitivity analysis: excluding studies with serious missing data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.76 [‐20.55, ‐18.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 HDL‐C (end of follow up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.30, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 HDL‐C (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.30, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 HDL‐C (end of follow up) (sensitivity analysis: excluding studies with serious missing data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.29, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 TG (end of follow up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.58 [‐33.67, ‐21.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 TG (end of follow up) (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.88 [‐39.50, ‐26.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 TG (end of follow up) (sensitivity analysis: excluding studies with serious missing data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.68 [‐33.96, ‐21.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012502.pub2/references#CD012502-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012502.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012502-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012502-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012502-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012502-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012502-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012502-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012502-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012502-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012502\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012502\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012502\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012502\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012502\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012502.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012502.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012502.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012502.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012502.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716537486"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012502.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716537490"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012502.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da1e61ce09379',t:'MTc0MDcxNjUzNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 